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The chromatin-associated protein WDR5 is a prom-
ising target for pharmacological inhibition in cancer.
Drug discovery efforts center on the blockade of
the ‘‘WIN site’’ of WDR5, a well-defined pocket that
is amenable to small molecule inhibition. Various
cancer contexts have been proposed to be targets
for WIN site inhibitors, but a lack of understanding
of WDR5 target genes and of the primary effects
of WIN site inhibitors hampers their utility. Here,
by the discovery of potent WIN site inhibitors, we
demonstrate that the WIN site links WDR5 to chro-
matin at a small cohort of loci, including a specific
subset of ribosome protein genes. WIN site inhibi-
tors rapidly displace WDR5 from chromatin and
decrease the expression of associated genes,
causing translational inhibition, nucleolar stress,
and p53 induction. Our studies define a mode by
which WDR5 engages chromatin and forecast that
WIN site blockade could have utility against multiple
cancer types.
INTRODUCTION
Increased awareness of the importance of epigenetic processes
in cancer has fueled interest in the concept that epigenetic
regulators can be targeted to treat malignancy. A collection of
epigenetic regulators has been subject to small molecule inhibi-
tion in recent years, including histone methyltransferases, his-
tone deacetylases, and proteins that bind modified histones.
There are dozens of small molecule epigenetic inhibitors in clin-
ical trials in the United States (Bennett and Licht, 2018), but as
the likelihood of approval of investigational oncology drugs is2916 Cell Reports 26, 2916–2928, March 12, 2019 ª 2019 The Autho
This is an open access article under the CC BY-NC-ND license (http://small, drugs against additional targets are needed to increase
the chances that one of these agents will improve our ability to
treat cancer.
One epigenetic regulator that has received considerable
attention as a cancer target is WDR5. WDR5 is a WD40-repeat
protein that scaffolds the assembly of multiple epigenetic
‘‘writers,’’ including the non-specific lethal (NSL) and Ada2-con-
taining (ATAC) histone acetyltransferase (HAT) complexes and
the MLL/SET-type histone methyltransferases (HMTs) that cata-
lyze histone H3 lysine 4 (H3K4) di- and tri-methylation (Guarnac-
cia and Tansey, 2018). Aberrant WDR5 expression is implicated
in a variety of cancers, such as leukemias (Ge et al., 2016), breast
cancer (Dai et al., 2015), and bladder cancer (Chen et al., 2015).
In addition, WDR5 has been shown to play a critical role in
promoting the epithelial-to-mesenchymal transition (Wu et al.,
2011), it serves as a co-factor for MYC (Carugo et al., 2016;
Thomas et al., 2015), and it is a promising therapeutic target
in a number of bloodborne and solid cancers (Cao et al., 2014;
Grebien et al., 2015; Zhu et al., 2015). Highly potent drug-like
inhibitors of WDR5—if they can be discovered—could have a
tremendous impact in the clinic.
From a structural perspective, the most obvious route to
pharmacologically inhibit WDR5 is via the WIN (WDR5 interac-
tion) site, a well-defined pocket that mediates interaction with
an arginine-containing motif (WIN motif; consensus ‘‘ARA’’) pre-
sent in multiple WDR5-interaction partners (Guarnaccia and
Tansey, 2018). Although the functions of the WIN site are not
fully understood, it is clear that the HMT activity of complexes
carrying the MLL1 protein, but not other mixed lineage leuke-
mia/Su(var)3–9, Ezh2, Trithorax (MLL/SET) family members, is
dependent on WIN site binding by a WIN motif (Alicea-Vela´z-
quez et al., 2016), leading to the concept that WIN site inhibitors
could alter transcriptional patterns by modulating H3K4
methylation. Consistent with this idea, a moderately potent
(Kd 100 nM) small molecule WIN site inhibitor inhibits cancer
cells that express mutant forms of CCAAT-enhancer-bindingr(s).
creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Discovery of Small Molecule WIN
Site Inhibitors
(A) Elaboration of fragment hit C1 into our first-
generation chemical probe C3.
(B–D) X-ray co-crystal structures of WDR5 bound
to (B) the fragment hit C1 (PDB: 6DY7), (C) C2
(PDB: 6E1Y), and (D) C3 (PDB: 6E22).
(E) Elaboration of fragment hit C4 into our second-
generation chemical probe C6.
(F–H) X-ray co-crystal structures of WDR5 bound
to (F) the fragment hit C4 (PDB: 6E1Z), (G) C5 (PDB:
6DYA), and (H) C6 (PDB: 6E23).
See also Figure S1 and Tables S1 and S2.protein a (C/EBPa) (Grebien et al., 2015) and p53 (Zhu et al.,
2015). Additionally, higher affinity (Kd 1 nM) peptidomimetics
against the WIN site temper H3K4 methylation and inhibit leuke-
mia cells bearing rearrangements in the MLL1 gene (Cao et al.,
2014). Whether WIN site inhibitors work by directly affecting
H3K4 methylation or whether these changes are a secondary
consequence of some other perturbation of the WIN site, how-
ever, is unknown. Compounding this issue is the relative lack of
understanding of the types of genes controlled by WDR5, mak-
ing it difficult to predict the primary transcriptional conse-
quences of WIN site blockade.
Given the therapeutic potential of targeting WDR5 in cancer,
we sought to independently discover small molecule inhibitors
of the WIN site and to characterize their primary mechanism
of action in the well-studied context of MLL1-rearranged
(MLLr) cancer cells. Here, we used fragment-based approaches,
coupled with structure-based design, to identify inhibitors that
bind tightly to the WIN site of WDR5—in our best case, with an
affinity in the picomolar range. We show that these inhibitors
result in the rapid and comprehensive displacement of WDR5
from chromatin and lead to a commensurate decrease in the
expression of WDR5-bound genes. We also define how these
compounds inhibit proliferation and induce apoptosis in MLLr
cancer cells. These studies reveal a primary mechanism of ac-
tion of WIN site inhibitors, illuminate gene regulatory networks
driven by WDR5, and forecast that drug-like WIN site inhibitors
could have broad anti-cancer activity.Cell ReRESULTS
Discovery of WIN Site Inhibitors
To identify small molecules that bind
the WIN site, we conducted a fragment-
based screen of 13,800 compounds by
acquiring SOFAST 1H-15N heteronuclear
multiple quantum coherence (HMQC)
spectra of WDR5 (Wang et al., 2018).
An initial HMQC spectrum of uniformly
15N-labeled WDR5 with an unlabeled
MLL1WIN peptide highlighted peak shifts
that correspond to amino acids in the vi-
cinity of the WIN site. Mixtures of 12 frag-
ments were incubated with labeledWDR5
protein, and those that caused peak shifts
similar to the MLL1 peptide were flaggedas WIN site hits. Follow-up screening of individual compounds
from the hit mixtures identified 47 hits. One of these fragment
hits is compound C1 (Figure 1A), which binds WDR5 with a Kd
of 66 mM (Table S1). We solved the X-ray crystal structure of
C1 when complexed with WDR5 (Figure 1B; Table S2) and found
that the cyclic guanidine of C1 binds deep into the S2 pocket
of WDR5 (Wang et al., 2018), mimicking the arginine of
the WIN peptide. To improve the affinity of C1, we used struc-
ture-based design to access nearby pockets. Growing out to
S7 with a benzyl amide yielded compound C2 (Figure 1A), with
a 3,000-fold improvement in affinity. In the X-ray structure of
WDR5 bound to C2 (Figure 1C; Table S2), the benzyl group oc-
cupies the S7 pocket, anchored by additional hydrogen-bonding
interaction of the carbonyl oxygen with the backbone NH of Cys-
261. Further optimization of C2 led to C3 (Figure 1A), with a Kd of
1.3 nM. Compound C3 provides improved potency by modifying
the substituents on the benzylic ring to better occupy the S7
pocket and by inclusion of a fluorine atom on the phenyl core
that points toward the S4 pocket (Figure 1D; Table S2). C3
is our first-generation chemical probe to explore the cellular
consequences of WIN site blockade. To aid in these studies,
we designed a negative control compound, C3nc (Figure S1A),
that has the same molecular weight as C3 but binds WDR5
with reduced affinity due to the regioisomeric fluorine atom
that clashes with the protein.
To obtain amore potent probe, we startedwith a different frag-
ment hit (C4; Figure 1E). Although C4 bound the S2 pocket asports 26, 2916–2928, March 12, 2019 2917
Table 1. Cellular Sensitivity to WIN Site Compounds and Their Matching Negative Controls
Cell Line C6 GI50 (mM) C6nc GI50 (mM) C3 GI50 (mM) C3nc GI50 (mM) p53 Status Notable Mutations
MV4:11 3.20 ± 0.213 42.0 ± 9.02 6.67 ± 0.519 >50 WT MLL–AF4, FLT3/ITD
Molm13 6.43 ± 0.683 >50 10.3 ± 1.03 >50 WT MLL–AF9, FLT3/ITD
HL60 14.8 ± 1.10 >50 >50 >50 null Nras (Q61L)
K562 25.4 ± 2.07 31.7 ± 2.45 >50 >50 null (Q136fs)
THP-1 >50 >50 >50 >50 null (C174fs) MLL-AF9, Nras (G12D)
HEL >50 >50 >50 >50 M133K JAK2 V617F
NOMO-1 >50 >50 >50 >50 null (C242fs) MLL-AF9
SET-2 >50 >50 >50 >50 R248W (GOF) JAK2 V617F
MONO-Mac-6 31.7 ± 2.32 >50 ND ND R273H MLL-AF9
GDM-1 >50 >50 ND ND WT
MA93 5.04 ± 0.431 30.3 ± 5.94 22.1 ± 3.60 >50 p53+ MLL-AF9
MA93 FLT3-ITD 2.47 ± 0.137 26.2 ± 4.75 21.2 ± 2.11 >50 p53+ MLL-AF9, FLT3/ITD
MA93 Ras 20.75 ± 2.625 >50 >50 >50 p53+ MLL-AF9, Nras (G12D)
RN2 11.2 ± 1.48 >50 8.65 ± 0.989 >50 p53+ MLL-AF9, Nras (G12D)
The indicated cell lines were treated with at least a five-point serial dilution set of compounds for 3 days, and cell numbers determined by either MTS
assay (RN2) or CellTiter-Glo (all other lines). Cell numbers for each dose were normalized to those from DMSO-treated samples and used to calculate
mean GI50 values, which are shown along with SEMs. The p53 status of each cell line is shown; MA93, MA93 FLT3-ITD, MA93 Ras, and RN2 cells are
positive for the expression of p53 protein (p53+), but whether p53 is mutant in these cells is unknown. Mutation information was collected from ATCC,
DMSZ, or the Broad Institute Cancer Cell Line Encyclopedia. >50, the top concentration used (50 mM) did not reduce cell number below 50%. ND, not
determined. See also Figure S2.shown in the X-ray structure (Figure 1F; Table S2), it did not bind
to any of the nearby binding sites. Accessing the S7 pocket (Fig-
ure 1G; Table S2) led to compound C5, which has improved
binding affinity. A further improvement in affinity was achieved
by occupying the S4 pocket with compound C6 (Figures 1H,
S1B, and S1C; Table S2). C6 has a Kd of 100 pM and served
as our second-generation chemical probe. As with C3, we ob-
tained a negative control, C6nc, in this instance by adjusting
the attachment point of the S2 imidazole-imine ‘‘warhead’’ to
yield a compound with a >1,000-fold reduction in binding affinity
(Figure S1A). For C3 and C6, we performed direct affinity mea-
surements using surface plasmon resonance and found that
in both cases their affinity for WDR5 was within 2-fold of the
values calculated by time-resolved fluorescence energy transfer
(TR-FRET) (Figure S1D). Representative data from affinity
measurement experiments is shown in Figures S1E and S1F.
As expected, C3 and C6 inhibit the HMT activity of MLL/SET
complexes containing MLL1 and do so in a manner that reflects
their affinity for the WIN site (Table S1). Profiling C6 against all
MLL/SET complexes (Table S1), we found the inhibition to be
specific forMLL1, with little activity against otherMLL/SET family
members. We used C3 and C6 and their negative controls to
interrogate the biological consequences of WIN site blockade.
C3 and C6 Inhibit Leukemia Cell Lines In Vitro
The WIN site peptidomimetic MM-401 inhibits cell lines and
primary transformed cells carrying MLL1 rearrangements (Cao
et al., 2014). We asked whether C3 and C6 show similar activity.
We profiled a collection of human leukemia lines, as well as hu-
man CD34+ cord blood cells transformed by the expression of
an MLL-AF9 fusion protein (MA93), either alone or in conjunc-
tion with FMS-like tyrosine kinase-3-internal tandem duplication2918 Cell Reports 26, 2916–2928, March 12, 2019(FLT3-ITD) (MA93 FLT3-ITD) or NrasG12D (MA93 Ras) onco-
genes (Wei et al., 2008). We also tested the murine Mll-Af9;
NrasG12D cell line RN2, derived from the spleens of terminally
ill leukemic mice (Mazurek et al., 2014). We treated cells with
increasing doses of compounds for 3 days and measured viable
cell numbers compared to DMSO-treated controls (Table 1).
Four trends were apparent from this analysis. First, MLLr cell
lines are generally more sensitive than non-MLLr cells to both
C3 and C6. Second, the tighter WIN site binder C6 has higher
cellular potency than C3 in all sensitive lines. Third, negative
control compounds C3nc and C6nc have little, if any, activity
in any cell type. Fourth, a robust response to these inhibitors
appears to correlate with p53 status, as MLLr leukemia lines
with wild-type (WT) p53 were more sensitive than lines with
mutant p53.
For two representative cell lines, MV4:11 (sensitive) and
K562 (insensitive), we performed cellular thermal shift assays
(CETSAs) (Jafari et al., 2014) to track the ability of compounds
to bind WDR5 in vivo (Figure S2). For both compounds, we
observed a significant decrease in target engagement compared
to their affinity for WDR5, with half-maximal effective concentra-
tion (EC50) values in cells being between 600- and 2000-fold
higher than Kd values measured with purified WDR5 in vitro.
Nonetheless, we found that the ability of C3 and C6 to bind
WDR5 in cells tracks with compound potency and that there
are no major differences in how each compound interacts
with WDR5 in each cell type. Differential cellular response to
these compounds, therefore, is not due to differences in target
engagement. These data demonstrate that C3 and C6 inhibit
MLLr lines in vitro in a manner that reflects their relative affinities
for WDR5, and they suggest that p53 may be involved in the
cellular response to these inhibitors.
Figure 2. WIN Site Inhibition Induces
Apoptosis and Kills Cells in a p53-Depen-
dent Manner
(A) MV4:11 cells were treated with DMSO, 2 mM
C6, or C6nc; samples collected at the indicated
time points; and live cells quantified via trypan
blue exclusion. To prevent culture overgrowth, the
DMSO- and C6nc-treated samples were replated
at day 3 (‘‘replate’’) to the original starting density
and treatment continued.
(B) Stacked bar graph showing the distribution of
cell-cycle phases, determined by flow cytometry,
in MV4:11 cells treated with DMSO, 2 mMC6nc, or
C6 for the indicated times.
(C) Western blot for cleaved PARP-1 (P-cl), or
histone H3, in lysates from MV4:11 cells treated
with DMSO, 2 mM C6nc, or C6 for the indicated
times.
(D) Bar graph showing the percentage of an-
nexin V+ and propidium iodide-negative (PI) cells
in MV4:11 cells treated with DMSO, 2 mM C6nc,
or C6 for the indicated days. Camptothecin
(CPT) is a positive control for the induction of
apoptosis.
(E) Western blot, showing the effects of DMSO,
2 mM C6, or C6nc (24 h), on p53 and p21 protein
levels in MV4:11 cells. Histone H3 is a loading
control.
(F) Western blot, showing p53 levels in MV4:11
cells treated with 2 mM C6nc or C6 for 24 h, and
expressing either (1) a scrambled shRNA control
(scr), (2) shRNA 427 against p53 (sh_427), or (3)
shRNA 941 against p53 (sh_941).
(G) Dose-response curves for compound C6 and
its negative control, C6nc, in MV4:11 cells ex-
pressing the indicated shRNAs. GI50 results from
3-day treatment with C6 are shown to the right of
the appropriate curves.
(H) Western blot, showing the effects of DMSO,
3 mM C6, or C6nc (24 h), on p53 and p21 protein
levels in Molm13 cells.
(I) Western blot, showing p53 levels in the clones
of Molm13 cells that were CRISPR targeted
with either an EGFP (clones 2e and 3e) or a p53
(clones 2p and 4p) guide RNA (gRNA). Cells were
treated with C6 or C6nc at 3 mM for 24 h before
analysis.
(J) Dose-response curves for compound C6 (3-day treatment) in the modified Molm13 cells described in (I). The GI50 values are 7 mM for clones 2e and 3e, 18 mM
for clone 2p, and 15 mM for clone 4p.
(A, D, G, and J) Error bars represent SEM.
See also Figure S3.WIN Site Inhibition Induces p53-Dependent Cell Death
We asked how C6 inhibits MV4:11 cells in culture. A time-course
analysis revealed that inhibition of proliferation can be detected
within a few days of treatment at the 50% growth inhibition (GI50)
concentration (Figure 2A) and that between 2 and 6 days of treat-
ment, there is a progressive decrease in cellular viability (Fig-
ure S3A). Analysis of cell-cycle distribution demonstrated that
C6 caused a time-dependent increase in cells with a sub-G1
DNA content (Figures 2B and S3B), which is consistent with
the induction of programmed cell death. Probing for more sensi-
tive and direct hallmarks of apoptosis, we found that C6
promotes the caspase-mediated cleavage of poly (ADP-ribose)
polymerase 1 (PARP-1) (Figure 2C), as well as the appearanceof apoptotic cells, asmeasured by annexin V staining (Figure 2D).
Notably, we could detect cleaved PARP-1 within 24 h following
treatment, indicating that C6 begins to initiate apoptotic pro-
cesses soon after exposure.
Because p53 status appears to correlate with sensitivity to our
WIN site inhibitors (Table 1), we askedwhether p53 is induced by
C6 and whether the cellular inhibition we observe in response to
C6 is p53 dependent. Western blotting demonstrated that a 24-h
treatment of MV4:11 cells with C6 moderately induces p53, as
well as the canonical p53 target gene p21 (Figure 2E). To deter-
mine whether p53 status affects compound sensitivity, MV4:11
cells were transduced to express one of two short hairpin
RNAs (shRNAs) against p53, or a scrambled shRNA control,Cell Reports 26, 2916–2928, March 12, 2019 2919
Figure 3. WIN Site Blockade Inhibits WDR5-Bound Genes Linked to Protein Synthesis
(A) Table shows the number of transcripts significantly (FDR < 0.05) altered by 3 days of treatment of MV4:11 cells with 2 mM C6 or C6nc, compared to DMSO
control.
(B) Gene Ontology (GO) enrichment clusters for genes significantly repressed by C6 treatment of MV4:11 cells, as determined by RNA-seq. Numbers in italics
represent the number of repressed genes in each category.
(C) Highly significantly enriched (FDR q = 0.0) Reactome gene sets (defined in the Molecular Signatures Database), determined by gene set enrichment analysis
(GSEA) of RNA-seq from MV4:11 cells treated with 2 mM C6.
(D) Overlap of genomic binding sites for WDR5 in MV4:11 cells, as determined by ChIP-seq with either the D9E1I or 429A anti-WDR5 antibodies.
(E) Top eight GO enrichment categories for genes bound by WDR5 in DMSO-treated MV4:11 cells.
(legend continued on next page)
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and treated for 3 days with C6nc or C6. These shRNAs reduce
steady-state p53 levels to different extents (Figure 2F), but
both decrease the sensitivity to C6 (Figure 2G) and do so in a
manner that correlates with the extent of p53 knockdown; the
least effective shRNA against p53 (shRNA_427) increased the
GI50 of C6 from 2 mM to 8 mM, whereas the most potent
(shRNA_941) increased the GI50 to 15 mM. To confirm these find-
ings, we used CRISPR-mediated genome editing to create p53
null clones of MV4:11 cells (Figure S3C) and found that these
clones also have a reduced sensitivity to C6 (Figure S3D). Finally,
we showed that p53 and p21 are also induced by 24-h C6 treat-
ment in Molm13 cells (Figure 2H) and that CRISPR-generated
p53 null Molm13 clones (Figure 2I) are less sensitive to C6 than
clones in which p53 is intact (Figure 2J). Based on these findings,
we conclude that WIN site inhibition induces p53 within 1 day of
exposure and that a significant portion of the mechanism of
cellular inhibition in response to C6 is p53 dependent.
WIN Site Inhibition Represses WDR5-Bound Genes
Involved in Protein Synthesis
To illuminate themechanism through which cells respond toWIN
site inhibition, we performedRNA-sequencing (RNA-seq), exam-
ining the effects of a 3-day treatment of MV4:11 cells with C6 or
C6nc (Figure S4A). Consistent with its lack of biological activity,
C6nc had no significant effect on gene expression levels in these
cells (Figure 3A). CompoundC6, in contrast, resulted in a number
of significant gene expression changes, increasing the expres-
sion of 72 genes and decreasing the expression of 462 genes
(Figure 3A). Gene Ontology (GO) enrichment analysis failed
to identify strong biological clustering among C6-induced
genes (Figure S4B), but for repressed genes we identified two
highly significant annotation clusters (Figure 3B). Cluster 1 is
connected to protein synthesis and is composed of a subset of
large and small ribosome protein genes (RPGs), some nuclear
encoded mitochondrial RPGs, and translation initiation factors.
Cluster 2 is connected to DNA replication and the cell cycle
and includes cyclins and cyclin-dependent kinases, as well as
DNA replication factors such as proliferating cell nuclear antigen
(PCNA) and components of the mini-chromosome maintenance
protein (MCM) complex. Gene set enrichment analysis (GSEA)
(Subramanian et al., 2005) strengthened these connections,
with highly significant (false discovery rate [FDR] q = 0.0) enrich-
ments in pre-ranked Reactome gene sets connected to transla-
tion, DNA replication, the cell cycle, and cell-cycle checkpoints
(Figure 3C), andGO gene sets connected to the ribosome, trans-
lation initiation, and DNA helicase activity (Figure S4C). From this
analysis, we conclude that WIN site inhibition decreases the
expression of specific sets of genes that are connected to pro-
tein synthesis and the cell cycle and DNA replication.
It is reasonable to expect that the gene expression changes
that we observe in response toWIN site inhibition are a combina-
tion of primary changes resulting from WIN site blockade and(F) Distribution of WDR5 binding sites in MV4:11 cells, binned according to the di
events (Set-wide) or only those at RPGs (Ribosome). RGA, region-gene associat
(G) Venn diagram, showing overlap of genes bound by WDR5 (ChIP-seq), with g
(H) As in (G), except overlap is between the genes bound by WDR5 and those re
See also Figure S4.secondary changes that occur in response to the primary pertur-
bations. It is also reasonable to expect that WDR5-bound genes
will most likely be the primary targets of WIN site inhibitors. To
focus our studies, therefore, we performed chromatin immuno-
precipitation coupled to next-generation sequencing (chromatin
immunoprecipitation sequencing [ChIP-seq]) to determine the
location of WDR5 on chromatin in MV4:11 cells. Using a mono-
clonal antibody against WDR5 (D9E1I; Cell Signaling Technol-
ogy), we tracked 158 high-confidence binding sites for WDR5
(Table S3), themajority of whichwere also detected by a different
anti-WDR5 antibody (429A; Bethyl Laboratories) (Figure 3D;
Table S3). These WDR5-binding sites are predominantly pro-
moter proximal (Table S3), and among WDR5-bound genes we
observed a strong biological clustering under GO terms con-
nected to the ribosome (Figure 3E). Indeed, WDR5 is bound to
a specific subset of RPGs, corresponding to genes encoding
40% of the small and70% of the large ribosome subunit pro-
teins. Binding of WDR5 to these genes occurs almost always
within 500 bp downstream of the transcription start site (TSS;
Figure 3F). We also observed WDR5 binding to genes encoding
a subset of translation initiation factors (Table S3). This pattern of
binding to specific RPGs is observed across disparate cell types
(Figure S4D), suggesting that these RPGs are a major—and
conserved—class of genes bound by WDR5. Comparing
the ChIP-seq and RNA sequencing (RNA-seq) datasets, we
observed that there is a strong tendency forWDR5-bound genes
to be repressed by C6 treatment. Only 1 WDR5-bound gene
is induced by C6 (Figure 3G), in contrast to 59 (37%) that are
repressed (Figure 3H). Of the 59 repressed genes, 39 encode
subunits of the ribosome, supporting the concept that these
RPGs may be direct targets of WIN site blockade. Notably,
we did not observe genes connected to the cell cycle or DNA
replication (cluster 2) in the WDR5 ChIP-seq data, suggesting
that changes in the expression of these genes may be a second-
ary consequence of WIN site inhibition.
Finally, we asked whether OICR-9429 (Grebien et al., 2015), a
chemically distinct WIN site inhibitor, acts similarly to C6. OICR-
9429 is less potent than C6, having a 3-day GI50 in MV4:11 cells
of 31 mM (Figure S4E), compared to 2 mM for C6 (Table 1). When
MV4:11 cells were treated with equal concentrations of OICR-
9429 and C6, only C6 inhibited the transcription of RPGs
(Figure S4F). When the concentrations were adjusted to reflect
the relative GI50 values, however, OICR-9429 selectively in-
hibited the transcription of WDR5-bound RPGs (Figure S4F)
and induced both p53 and p21 (Figure S4G). Thus, despite differ-
ences in potencies, repression of RPG transcription and induc-
tion of p53 are common actions of WIN site inhibitors.
Together, these findings expose a link betweenWDR5 and the
ribosome protein genes and suggest that this class of genesmay
be a direct target of WIN site inhibitors. By extension, these find-
ings also suggest that WIN site inhibitors may act in cells by dis-
rupting the integrity of the protein synthesis machinery.stance from the annotated TSS. Output includes either all of the WDR5 binding
ion.
enes induced by C6 treatment (RNA-seq) in MV4:11 cells.
pressed by C6 treatment.
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Figure 4. WIN Site Blockade Induces Translational Stress and Stimulates p53 Synthesis
(A) Representative flow cytometry histograms showing Alexa Fluor 647-labeled OPP incorporation into nascent polypeptides of MV4:11 cells treated with DMSO,
2 mM C6nc, or C6. As a control for the inhibition of translation, CHX was added to cells 30 min before the addition of OPP.
(B) Quantification of the nucleolus:nuclear ratio of NPM1 in MV4:11 cells treated with 4 mM C6 (or C6nc) for 3 days. ns, no significant difference (p = 0.1).
****p < 0.0001. Data are shown as a box and whisker plot. Box extends from the 25th to 75th percentile with median marked by the middle line, whiskers extend
from minimum to maximum point.
(C) MV4:11 cells were treated with DMSO, 2 mMC6, or 2 mMnutlin-3 for 24 h, after which CHXwas added and proteins sampled at the indicated time points (CHX;
in min). p53 and histone H3 (loading control, shown here for the C6 treatment) were detected by Western blotting.
(D) RT-qPCR analysis of the indicated mRNA levels on polysomal or monosomal fractions collected following the treatment of MV4:11 cells with 5 mM C6 or
DMSO for 24 h. Data are shown as a box and whisker plot of relative mRNA changes of indicated genes in each fraction, relative to DMSO. Box extends from the
25th to the 75th percentile, with the median marked by the middle line; whiskers extend from minimum to maximum point; n = 3 experiments.
See also Figure S5.WIN Site Inhibition Promotes Translational Stress and
Stimulates p53 Protein Synthesis
To determine whether WIN site blockade affects protein synthe-
sis, we treated MV4:11 cells for 1–6 days with C6, pulsed with
O-propargyl-puromycin (OPP) to label nascent polypeptide
chains (Liu et al., 2012), and we quantified OPP incorporation
by fluorescent OPP tagging and flow cytometry (Signer et al.,
2014). As early as 1 day after treatment, C6 caused ameasurable
reduction in OPP incorporation (Figures 4A and S5A), with mean
OPP fluorescence decreasing and shifting toward that observed
in the presence of the protein synthesis inhibitor cycloheximide
(CHX). The impact of C6 on protein synthesis capacity increased
across the time course of the experiment, and at 6 days, roughly
half of the cells in the C6-treated population incorporated OPP at2922 Cell Reports 26, 2916–2928, March 12, 2019levels similar to those of cells treated with CHX. Consistent with
diminished translational capacity, C6-treated MV4:11 cells also
displayed redistribution of nucleophosmin (NPM1) from the
nucleolus to the nucleoplasm (Figures 4B and S5B), a character-
istic of nucleolar stress (Russo and Russo, 2017). Thus, aligned
with decreased expression in protein synthesis components,
C6 imposes a choke on the translational capacity ofMV4:11 cells
and triggers nucleolar stress.
Wewere curious to know themechanism through which p53 is
induced in response to C6. Nucleolar stress itself can induce
p53, via disruption of the HDM2-p53 interaction that leads to
stabilization of the p53 protein (Russo and Russo, 2017), but
there are also indications that p53 protein synthesis can be
induced when cap-dependent translation is perturbed (Harris
et al., 2018). Because DNA damage can induce p53 at the levels
of both synthesis and turnover, we first showed that C6 does not
induce a robust DNA damage response, as measured by the
accumulation of g-H2AX foci (Figures S5C and S5D). Next, we
performed CHX-chase assays to monitor the proteolytic turn-
over of p53 in response to C6. As a control, we compared the ef-
fects of C6with those of nutlin-3, a small molecule inhibitor of the
HDM2-p53 interaction (Nicolae et al., 2014). Here (Figure 4C), as
expected, nutlin-3 increased the stability of p53 in response to
CHX treatment. Compound C6, in contrast, had no detectable
effects on p53 turnover. The induction of p53 that we observe
in response to WIN site inhibition, therefore, is unlikely to be
due to an increase in the metabolic stability of the protein.
To monitor for the induction of p53 translation, we asked how
C6 treatment altered the amount of TP53 mRNA on polysomes
versus monosome fractions (Yang et al., 2006). Here, we found
that C6 promoted an accumulation of polysome-associated
mRNAs for TP53 and a p53 target gene, TP53IPN1 (Figure 4D).
The increase in TP53 mRNA on the polysome fraction, amidst
a backdrop of decreased translation (Figure 4A), strongly implies
that WIN site inhibition induces p53 via a selective induction of
TP53 mRNA translation.
WIN Site Inhibitors Rapidly Displace WDR5 from
Chromatin and Inhibit RPG Transcription
All of the studies of WIN site inhibitors to date have examined the
transcriptional or epigenetic consequences ofWIN site blockade
over a relatively long time frame (e.g., >48 h). The low temporal
resolution of these studies makes it difficult to separate cause
from effect, and thus to determine the primary mechanism of ac-
tion of the compounds. We reasoned that the primary transcrip-
tional effects of WIN site inhibitors should manifest early, and
therefore, we looked at transcriptional and epigenetic changes
that occur within a few hours of compound treatment.
To monitor transcription, we used precision nuclear run-on
sequencing (PRO-seq) (Kwak et al., 2013; Zhao et al., 2016), a
global nuclear run-on approach, to ask how the distribution of
active RNA polymerases is altered across the genome soon after
WIN site blockade. MV4:11 cells were treated with C3 for 0, 15,
30, or 60 min and PRO-seq performed to follow changes in the
distribution of active RNA polymerases. This analysis (Figures
5A and 5B) identified a set of 47 transcription units (45 loci) in
which WIN site inhibition caused a significant decrease in gene
body transcription. There were no instances in which C3 pro-
moted an increase in transcription. In general, transcriptional
changes at these repressed genes were significant (padj =
0.0007–1028) and modest (1.5- to 2-fold), and most were
captured at the 15-min time point, indicating that C3 acts quickly
to influence transcriptional processes. Almost all of the genes
repressed by compound treatment are bound by WDR5 (Fig-
ure 5A), and a majority (70%) encode ribosome subunits.
Moreover, within the RPGs, we observed a consistent pattern
of genes occupied by WDR5, scored as repressed by PRO-
seq, and scored as repressed in RNA-seq experiments (Fig-
ure S6A), indicating that these genes are a direct and persistent
transcriptional target of WIN site blockade.
To look at accompanying epigenetic changes, we monitored
histone H3K4 trimethylation, which is appropriate given thatboth C3 and C6 are potent inhibitors of MLL1 complex HMT ac-
tivity (Table 1). After 4hofC3 treatment, however—well after tran-
scriptional effects are evident (Figure 5A)—there is little, if any,
change in the H3K4me3 status of select WDR5-bound genes
(Figure S6B). As a control in these experiments, WDR5 was
examined under these same conditions, and we were surprised
to see that C3 treatment resulted in a >10-fold reduction in
WDR5 binding at all five loci (Figure 5C). These changes in chro-
matin bindingwere not due to changes in the levels ofWDR5 (Fig-
ure S6C). Consistent with the ChIP results, treatment with C3
reduced the total amount of chromatin-boundWDR5 (Figure 5D;
‘‘P3’’ fraction), with a commensurate increase in WDR5 in the
soluble (S2) and solubilized nuclear fractions (S3). To determine
whether displacement of WDR5 from chromatin is a bona fide
consequence ofWIN site blockade, we engineered HEK293 cells
to express FLAG epitope-tagged WDR5; WT, or a mutant in
which phenylalanine 133—which makes critical interactions
with the guanidinium of the arginine in theWINmotif—is changed
to alanine (F133A). These forms of WDR5 were expressed
equally, and the F133A mutant retained the ability to interact
with RBBP5 (Figure S6D). When we examined chromatin binding
by ChIP, however, we could not detect binding of the F133A
WDR5 mutant to any of the loci tested (Figure 3E). The parallel
effects of chemical and genetic blockade of the WIN site reveal
that a prominent role of this site is to link WDR5 to chromatin.
Finally, we extended these analyses to our more potent com-
pound C6 and performed ChIP-seq for WDR5 in MV4:11 cells
treated for 4 h with either C6nc or C6 (Figure 5F). Compound
C6nc had little impact on WDR5 binding. Compound C6, in
contrast, resulted in a robust decrease in all detectable WDR5
binding events, with no measurable effect on WDR5 levels (Fig-
ure S6C). Based on these data, we conclude that the primary
mechanism of action of our WIN site inhibitors is to rapidly
displace WDR5 from chromatin, resulting in a commensurate
decrease in the expression of a subset of WDR5 target genes.
DISCUSSION
The discovery of small molecule inhibitors of epigenetic proteins
not only opens new opportunities for drug discovery but also
allows for the interrogation of the mechanisms through which
these proteins work. Here, we discovered potent small mole-
cules that bind tightly to the WIN site of WDR5 and used these
to explore the impact of WIN site blockade on the interaction
of WDR5 with chromatin, transcriptional patterns, and cellular
functions. Our studies reveal that WDR5 is bound to a relatively
small cohort of loci, enriched in a specific subset of ribosome
protein genes. Chemical perturbation of the WIN site displaces
WDR5 from these loci, resulting in a rapid and persistent
decrease in the expression of WDR5-bound RPGs, induction
of translational stress, increased p53 translation, and activation
of p53-dependent apoptosis. These findings demonstrate that
WDR5 is amajor regulator of ribosome protein gene transcription
and forecast that WIN site inhibitors could have broad utility for
cancer treatment.
One of the major conclusions from this study is that the WIN
site links WDR5 to chromatin. This conclusion is supported by
findings with both C3 and C6 and with the F133A WDR5 mutant,Cell Reports 26, 2916–2928, March 12, 2019 2923
Figure 5. WIN Site Inhibitors Act Rapidly to
Displace WDR5 from Chromatin and Inhibit
Transcription at WDR5-Bound Genes
(A) Heatmap listing genes with significant changes
in gene body-associated polymerases in MV4:11
cells treated with 36 mM compound C3, as deter-
mined by PRO-seq. The orange bar indicates
whether WDR5 is bound to the locus. RPS17 (*)
and RPL17(***) are listed twice, because two
distinct National Center for Biotechnology Infor-
mation Reference Sequence Database (RefSeq)
IDswere called for those loci. LOC100506548 (**) is
the read-through transcription from RPL37.
(B) Heatmaps displaying log2-transformed fold
change of PRO-seq read counts in 200 bp bins ± 5
kb around the TSS of loci showing gene body
changes after C3 treatment.
(C) ChIP-PCR analysis of WDR5 binding at 5 loci in
MV4:11 cells treated with DMSO (DM), or 36 mM
of C3 (or C3nc) for 4 h. Chromatin samples were
immunoprecipitated with an anti-WDR5 antibody
(D9E1l) or an immunoglobulin G (IgG) control. Data
are presented as a percentage of the signal for the
same amplicon in the input chromatin.
(D) Western blot, showing WDR5 distribution in
the soluble (S2), soluble nuclear (S3), or insoluble
chromatin (P3) fractions of MV4:11 cells treated for
4 h with DMSO or 36 mM of C3. Histone H3 is a
control for the specificity of the insoluble chromatin
fraction.
(E) ChIP-PCR analysis of FLAG (FL)-taggedWDR5,
wild-type (WT), or a WIN site mutant (F133A),
stably expressed in HEK293 cells. Vector cells are
the negative control; ChIP was performed with an
anti-FLAG antibody.
(F) Scatterplot of normalized average read counts
for WDR5 binding peaks in DMSO-, C6nc-, and
C6-treated MV4:11 cells. Peaks are ranked based
on read counts in DMSO-treated cells.
(C and E) Error bars represent SEM.
See also Figure S6.which is unable to bind WIN motif-containing peptides (Patel
et al., 2008). Although the WIN site binds at least a half-dozen
interaction partners (Guarnaccia and Tansey, 2018), none of
these partners have been proposed to recruit WDR5 to
chromatin. The ability of WIN site blockade to evict WDR5 from
its target genes, however, supports the idea that WDR5 is
linked to chromatin through the WIN site, either indirectly or by
engaging aWINmotif in a chromatin-resident protein. If the latter
is correct, then this protein may be one of the characterized WIN
site binders, but as there are thousands of proteins encoded in
the human genome that carry the core WIN motif (A-R-A/S/T),
it is likely that the factor(s) responsible for tethering WDR5 to
chromatin is yet to be identified. Clearly, a grasp of the complete
repertoire of WIN site binders is needed to fully recognize the
mechanism and utility of small molecule WIN site inhibitors.2924 Cell Reports 26, 2916–2928, March 12, 2019Critical in defining the primary mecha-
nism of action of WIN site inhibitors is
to determine which genes are directly
affected byWIN site blockade. Our exper-iments with both C3 and C6 clearly point to a specific subset of
RPGs as targets of WIN site inhibition. The extensive overlap be-
tween RPGs identified as targets of C3 in PRO-seq and those
identified as targets of C6 in RNA-seq reveals a highly consistent
mode of action of these two compounds. The consistency in
their mode of action is solidified by the fact that both C3 and
C6 displace WDR5 from chromatin and by our observation that
a distinct WIN site inhibitor, OICR-9429, shows the same selec-
tivity in RPG inhibition. Coupled with the recurring and highly
consistent binding of WDR5 to a select subset of RPGs in
different cell types, we conclude that these RPGs are a predom-
inant biological target of WDR5 and thus of WDR5 inhibitors.
The importance of ribosomes and altered ribosome biogen-
esis to cancer has long been known, but the links between
WDR5 and RPGs have not previously been reported. The Cancer
Dependency Map initiative (Tsherniak et al., 2017), which corre-
lated results from 500 genome-wide loss-of-function screens,
reported that 6 of the top 10 correlated dependency profiles for
WDR5 are RPGs, supporting the notion that WDR5 is meaning-
fully connected to ribosome homeostasis. Hyperactive ribosome
synthesis is a hallmark of many cancers (Pelletier et al., 2018),
and WDR5 has the potential to mediate altered RPG expression
in this context, either by its own overexpression (e.g., Chen et al.,
2015; Dai et al., 2015; Tan et al., 2017) or by working with onco-
proteins such as MYC (Carugo et al., 2016; Thomas et al., 2015).
What is difficult to reconcile, however, is why only a defined sub-
set of RPGs are under the control of WDR5 and what this means
for both normal cellular activities and altered ribosome function
in cancer. It is possible that the specific RPGs that are regulated
by WDR5 have some common property, as yet unknown, that
requires their coordinated expression via WDR5. Alternatively,
perhaps the biased distribution of WDR5 across the RPGs acts
as a nuclear sensor of oncogenic activity, an early surveillance
mechanism that induces ribosome subunit imbalance—and trig-
gers a pro-apoptotic stress response—when WDR5 (or factors
that work through WDR5) levels rise in a cancer cell. Regardless
of the significance of the WDR5-RPG connection, however,
it creates an opportunity to induce a translational choke and
trigger p53-dependent apoptosis in cancer cells, as discussed
below.
The utility of WIN site inhibition in the context of MLLr cancers
is well established, and our findings with C3 and C6 strengthen
this connection. Exactly why MLLr cells are sensitive to WIN
site blockade needs further study, but likely relates to the ability
of MLL-fusion oncoproteins to induce the transcription of genes
connected to ribosomal and nucleolar processes, which has
recently been recognized as an important and distinct part of
their transcriptional repertoire (Garcia-Cuellar et al., 2016). The
discrepancy between the affinity of these inhibitors for WDR5
in vitro and the concentrations needed to engage WDR5 in cells
and elicit a biological response demonstrates that additional
strides need to be made to increase the permeability of these in-
hibitors and/or their ability to accessWDR5when it is complexed
with other proteins. Nonetheless, the mechanism of action we
describe for these compounds, which is likely shared by other
WIN site inhibitors, does have important therapeutic implications
that transcend MLLr cancers.
For example, the overexpression of WDR5 is reported in
numerous malignancies, including leukemias (Ge et al., 2016),
breast cancer (Dai et al., 2015), and bladder cancer (Chen
et al., 2015). For cancers with frank WDR5 overexpression,
therefore, the ability of our inhibitors to displace WDR5 from
chromatin predicts that the functional impact of WDR5 overex-
pression in these cancers could be attenuated by pharmacolog-
ical WIN site blockade. Moreover, the mechanism of p53 induc-
tion in response to WIN site inhibition, which is independent of
changes in p53 protein stability, may also offer unique therapeu-
tic opportunities, as this is different from the effects of inhibitors
of the HDM2-p53 interaction, which have had mixed success in
the clinic (Stegh, 2012).
Although in this context WIN site inhibitors kill MLLr cells inde-
pendent of changes in H3K4 methylation, we note that our WIN
site compounds are potent inhibitors of MLL1-driven HMT activ-ity. The half-maximal inhibitory concentration (IC50) value for C6
is 20 nM compared to 320 nM for MM-401 (Cao et al., 2014),
with at least a 250-fold window of selectivity for MLL1 over other
MLL/SET complexes. The inhibition of MLL1-mediated H3K4
methylation has been shown to be a viable strategy for killing
cancer cells that express mutant forms of C/EBPa (Grebien
et al., 2015) and p53 (Zhu et al., 2015). In these cancers, as
well as others that areMLL1 dependent, the ability of these inhib-
itors to specifically target the HMT activity of MLL1 complexes
may be exploited for therapeutic gain.
Perhaps the most intriguing application of WIN site inhibitors,
however, relates to their ability to inhibit RPG transcription.
The concept of targeting ribosome biosynthesis has gained
momentum in recent years as a viable strategy to treat cancer
(Pelletier et al., 2018), and may hold promise in other diseases
of ribosome dysfunction, such as myelodysplastic syndrome
(Rinker et al., 2016). Most of the successes in this area have
centered on the inhibition of ribosomal RNA transcription
(Bruno et al., 2017). While these strategies progress, a comple-
mentary approach of targeting RPG synthesis via WIN site
blockade could have value. It is possible, for example, that
the specific pattern of RPG imbalance caused by WIN site
inhibitors has advantages over rRNA inhibition. As opposed to
a general inhibition of ribosome biogenesis, WIN site inhibitors
will only directly affect the expression of those RPGs to which
WDR5 is bound. Thus far, this group of RPGs appears to be
conserved, and if this conservation withstands further chal-
lenge, it will be possible to predict which RPGs will respond
to WIN site blockade. It is clear that ribosome dysgenesis in
cancer cells is not random and that specific patterns of RPG
alterations occur that can distinguish normal from malignant
cells and one type of cancer from another (Dolezal et al.,
2018). By systematic analysis of the relationship between
altered RPG expression and cellular sensitivity to WIN site inhi-
bition, it may be possible to develop targeted WIN site inhibitor
therapies matched to specific patterns of ribosome protein
gene alterations in cancer patients.STAR+METHODS
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loading control)
Cell Signaling Technology Cat# 9715S; lot# 20
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Rabbit anti-WDR5 DE91I antibody (ChIP and western blot) Cell signaling Technology Cat# 13105; lot# 1; RRID:AB_2620133
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Complete, EDTA-free Protease Inhibitor Cocktail Roche Cat# 11873580001
Formaldehyde Sigma-Aldrich Cat# 47608
Recombinant Murine IL-3 PeproTech Cat# 213-13
AC220 Selleck Chemicals Cat# S1526
C3 This study VU0660638
C3nc This study VU0807192
C6 This study VU0808641
C6nc This study VU0817566
DMSO Sigma Cat# D8418
NuPAGE sample reducing agent (10X) ThermoFisher Cat# NP0009
NuPAGE 4X LDS sample buffer ThermoFisher Cat# NP0008
Protease inhibitor cocktail Sigma Cat# P8340
Tween-20 Sigma Cat# P2287
SuperSignal West Dura Extended Duration Substrate ThermoFisher Cat# 34076
KAPA SYBR FAST qPCR Master Mix 2X Universal Kapa Biosystems Cat# KK4602
WDR5 (aa 22–334) This study N/A
MLL peptide (FITC-GSARAEVHLRKS) GenScript N/A
Thr-FAM peptide (ARTEVHLRKS-(Ahx-Ahx)(Lys-(5-FAM))) GenScript N/A
MuLV reverse transcriptase Life Tech Cat# N8080018
O-Propargyl-puromycin (OPP) Thermo Cat# C10459
Alexa Flour647-Azide Thermo Cat# A10277
Annexin V Binding Buffer Invitrogen Cat# V13246
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Alexa Flour488-conjugated Annexin V Thermo Cat# A13201
Propidium iodide Sigma Cat# 4864
Direct-zol RNA MiniPrep kit Zymo Research Cat# R2050
Nutlin-3 Santa Cruz Biotechnology Cat# Sc-45061
Recombinant human SCF PeproTech Cat# 300-07
Recombinant human TPO PeproTech Cat# 300-18
Recombinant human IL3 PeproTech Cat# 200-03
Recombinant human IL6 PeproTech Cat# 200-06
OPI media supplement HYBRI-MAX Sigma Cat# O5003-1VL
Cycloheximide RPI Cat# C81040-1.0
Camptothecin Selleck Chemicals Cat# S1288
Actinomycin D Sigma Cat# A1410
DRAQ5 Thermo Cat# 62254
Kanamycin Research Products
International
Cat# K22000
OICR-9429 Selleck Chemicals Cat# S7833
Isopropyl- b-D-thiogalactoside (IPTG) Research Products
International
Cat# I56000
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2-amine, (C1)
Enamine Cat# Z1090036110
N-(1-(3-Chlorophenyl)ethyl)-3-(((4,5-dihydro-1H-imidazol-2-
yl)amino)methyl)benzamide, (C2)
This study N/A
3-(((4,5-dihydro-1H-imidazol-2-yl)amino)methyl)-N-(3,5-
dimethoxybenzyl)-4-fluorobenzamide, (C3)
This study N/A
3-(((4,5-dihydro-1H-imidazol-2-yl)amino)methyl)-N-(3,5-
dimethoxybenzyl)-2-fluorobenzamide, (C3nc)
This study N/A
5-(1H-imidazol-1-ylmethyl)furan-2-carboxylic acid, (C4) Asinex Ltd. Cat# BAS 06502679
3-((1H-Imidazol-1-yl)methyl)-N-(3,5-
dichlorobenzyl)benzamide, (C5)
This study N/A
N-(3,4-Dichlorobenzyl)-3-(6-fluoro-2-methylpyridin-3-yl)-
5-((2-imino-3-methyl-2,3-dihydro-1H-imidazol-1-
yl)methyl)benzamide, (C6)
This study N/A
N-(3,4-dichlorobenzyl)-3-(6-fluoro-2-methylpyridin-3-yl)-
4-((2-imino-3-methyl-2,3-dihydro-1H-imidazol-1-
yl)methyl)benzamide, (C6nc)
This study N/A
Critical Commercial Assays
CellTiter-Glo Proliferation assay kit Promega Cat# G7572
CellTiter 96 AQueous MTS Reagent Powder Promega Cat# G1112
Gibson Assembly Cloning Kit New England Biolabs Cat# E5510S
DNA Ultra II Prep Kit for Illumina New England Biolabs Cat# E7645
Click-it Cell Reaction Buffer Kit Thermo Cat# C10269
MLL1 HMT Assay Reaction Biology Cat# MLL1
MLL2 HMT Assay Reaction Biology Cat# MLL2
MLL3 HMT Assay Reaction Biology Cat# MLL3
MLL4 HMT Assay Reaction Biology Cat# MLL4
Set1A Complex HMT Assay Reaction Biology Cat# HMT-15-116
SET1B Complex HMT Assay Reaction Biology Cat# HMT-15-117
Deposited Data
X-ray crystallography This study 6DY7, 6EY1, 6E22, 6E1Z, 6DYA, and 6E23
Genomic (Chip-, RNA-, and PRO-Seq) This study GSE115377
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Experimental Models: Cell Lines
MV4:11 ATCC Cat# CRL-9591; RRID:CVCL_0064
Molm13 DSMZ Cat# ACC554; RRID:CVCL_2119
K562 ATCC Cat# CCL-243; RRID:CVCL_0004
HEK293 FGH This study N/A
HEK293 FL-WDR5 This study N/A
HEK293 FL-F133A WDR5 This study N/A
SET-2 DSMZ ACC-608
HEL ATCC TIB-180
NOMO-1 DSMZ ACC-542
MA93 Wei et al., 2008 N/A
MA93 ras Wunderlich et al., 2013 N/A
MA93 FLT3/ITD Wunderlich et al., 2013 N/A
RN2 Zuber et al., 2011 N/A
GDM-1 ATCC Cat# ATCC CRL-2627; RRID:CVCL_1230
MONO-MAC-6 DSMZ Cat# ACC 124; RRID:CVCL_1426
THP-1 ATCC TIB-202
Oligonucleotides
See Table S4 for oligonucleotide sequences N/A N/A
Recombinant DNA
pBabe-PURO Morgenstern and Land, 1990 N/A
pET6xHis-SUMO–WDR5 This study N/A
pcDNA3.1-FLT3-C-(K)DYK GenScript Cat# OHu20276
pBabe-FLT3-ITD-C-(K)DYK-PURO This Study N/A
pCL10A1 Novus Biologicals Cat# NBP2-29542
pLKO-p53-shRNA-941 Kim et al., 2007 Addgene plasmid #25637
pLKO-p53-shRNA-427 Kim et al., 2007 Addgene plasmid #25636
Scramble shRNA pLKO.1 Sarbassov et al., 2005 Addgene plasmid #1864
pLentiCRISPRv2 Addgene Addgene plasmid #14748
pLentiCRISPRv2–TP53 This study N/A
pLentiCRISPRv2–EGFP This study N/A
pLKO.3G Addgene Addgene plasmid #14748
pLKO.3G-p53-shRNA-941 This study N/A
pLKO.3G-p53-shRNA-427 This study N/A
pLKO.3G-shRNA-scramble This study N/A
pMD2 (VSV-G Env) Provided by A. Reynolds N/A
pCMV-PAX2 (GAG and POL) Provided by A. Reynolds N/A
Software and Algorithms
FlowJo v10 FlowJo, LLC https://www.flowjo.com/
BD FACSDDiva 8.0 BD Biosciences http://www.bdbiosciences.com/us/
instruments/research/software/flow-
cytometry-acquisition/bd-facsdiva-
software/m/111112/overview
Prism 7 GraphPad https://www.graphpad.com/scientific-
software/prism/
Fiji version 1.0 Schindelin et al., 2012 https://fiji.sc/
HKL2000 HKL Research, Inc. https://www.hkl-xray.com/download-
instructions-hkl-2000
CCP4.45 CCP4 https://www.ccp4.ac.uk
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Phenix Phenix https://www.phenix-online.org
Coot MRC Laboratory of Molecular
Biology
http://www2.mrc-lmb.cam.ac.uk/
personal/pemsley/coot/
PyMol Schrodinger, LLC https://pymol.org/2/
XLFit ID Business Solutions https://www.idbs.com/excelcurvefitting/CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, William
Tansey (william.p.tansey@vanderbilt.edu).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell lines
MV4:11 (male), K562 (female), HL60 (female), Molm13 (male), HEL (male), SET-2 (female), NOMO-1 (female), GDM-1 (female), and
RN2 (female) cell lines were cultured in RPMI-1640 media with 10% FBS. THP-1 (male) cells were grown in RPMI-1640 media
with 0.05 mM 2-mercaptoethanol and 10% FBS. MA93 Ras (male) and MA93 FLT3/ITD (male) cells were grown in IMDM media
with 20% FBS. MA93 (male) cells were grown in IMDM media with 20% FBS, and 10 ng/mL recombinant human SCF/TPO/
FLT3L/IL3/IL6. MONO-MAC-6 (male) cells were grown in RPMI with 10% FBS, non-essential amino acids and OPI media
supplement. HEK293T (female) cells, and their derivatives, were maintained in DMEM supplemented with 10% FBS. All media
was supplemented with 100 IU/ml Penicillin and 100 mg/ml streptomycin. All cell lines were cultured at 37C with 5% CO2 and split
every 2-4 days; suspension cells were maintained at a cell density of between 1 3 105 and 1 3 106 cells/ml.
METHOD DETAILS
Protein Expression and Purification
Human WDR5 (aa: 22–334) was cloned into a modified pET vector (pBG104) with a 6xHis-SUMO tag present at the N terminus. The
plasmid was then transformed into E. coli BL21 (DE3) cells. One hundred milliliters of LB starter was used to inoculate a 10 l fermen-
tation culture (BioFlo 415, New Brunswick Scientific), grown at 37C. Fermentation growth media contained KH2PO4 (4 g/L), K2HPO4
(6 g/L), Na2SO4 (2 g/L), K2SO4 (1 g/L), NaCl (0.5 g/L), Yeast Extract (5 g/L), glycerol (2 ml/L), Antifoam (0.2 ml/L), 5% LB medium,
glucose (25 g/L), MgCl2 (2 mM), CaCl2 (0.1 mM), NH4Cl (2.5 g/L), and Kanamycin (50 mg/ml). When the cell density reached
OD600 = 2.0, the temperature was lowered to 30
C, and WDR5 expression induced by treatment with 1 mM isopropyl-b-D-thioga-
lactoside (IPTG) overnight. Cell pellets were collected, dissolved in lysis buffer containing 1XPBS plus 300 mM NaCl, 20 mM
imidazole, 5 mM BME, and 10% glycerol, and lysed by homogenization (APV-2000, APV). The lysate was cleared by centrifugation,
filtered, and then applied to the Ni-column (140 mL, ProBond, Invitrogen). Bound protein was eluted using an imidazole gradient
(0–300 mM). The His-SUMO-tag was cleaved by SUMO protease during dialysis and subsequently eliminated through a second
Ni-column. WDR5 protein was then purified by size-exclusion chromatography (HiLoad 26/60, Superdex 75, GE Healthcare) using
crystallization buffer consisting of 20 mM HEPES, pH 7.0, 250 mM NaCl, and 5 mM DTT. The purity of protein was checked using
SDS–PAGE. Purified WDR5 was then concentrated to 10 mg/mL, and was stored at 80C.
Protein Crystallization, Data Collection, and Structure Refinement
WDR5 apo- and co-crystals were obtained at 18C using the hanging drop method. The crystallization condition was 0.1 M Bis-Tris
pH 6.0, 0.2 M ammonium acetate, 28% to 32% PEG3350. A soaking method was applied for some of the compounds using WDR5
apo-crystals. Crystals were flash frozen directly in liquid nitrogen. Diffraction data were collected on the Life Sciences Collaborative
Access Team (LS-CAT) 21-ID-D and G beamlines at the Advanced Photon Source (APS) at Argonne National Laboratory. Diffraction
data were indexed, integrated, and scaled using HKL2000 (Otwinowski and Minor, 1997). Molecular replacement was applied using
Phaser44 as implemented in CCP4.45 (Winn et al., 2011) using a published structure (PDB code 3EG6). Refinement of the structural
models was performed using PHENIX (Adams et al., 2002) along with rounds ofmanual model building in COOT (Emsley and Cowtan,
2004). All structure images were prepared with PyMOL. A summary of the final refinement statistics for structures including
compounds C1–6 can be found in the Table S2.e4 Cell Reports 26, 2916–2928.e1–e13, March 12, 2019
FPA and TR-FRET Competition Assays
Fluorescein isothiocyante (FITC) labeledMLL peptide (FITC-GSARAEVHLRKS) and 10-mer-Thr-FAM (ARTEVHLRKS-(Ahx-Ahx)(Lys-
(5-FAM))) (Karatas et al., 2010) were purchased from GeneScript and used without additional purification. Anisotropy, fluorescence,
and TR-FRET emissions were recorded on a BioTek Cytation 3 instrument.
For the FITC-MLL FPA peptide assays, FITC-MLL peptide (FITC-GSARAEVHLRKS) was used at 50 nM, while WDR5was added at
theKd value of the protein:peptide interaction (WDR5–WINKd = 2.5 mM). Stock compoundswere dispensed in 384-well source plates
as 30mMsolutions in DMSO. An Echo Liquid Handler was used to distribute the compounds to the assay plates (384-well, black, flat-
bottom; Greiner) in a 10-point, 3-fold dilution, scheme in a final volume of 50 mL using a top concentration of 250 mM. Both the top
concentration and the dilution scheme were adjusted to fit the potency of the compounds to a lower Ki limit of 1 mM. For the FITC-
MLL assay, 2.5 mM WDR5 and 50 nM FITC-MLL peptide, in an assay buffer containing 1X Phosphate Buffered Saline (pH 6.0),
300mMNaCl, 0.5mMTCEP, and 0.1%CHAPS, were added to all compound-containing wells. To columns 1 and 23 (positive control,
100% inhibition) 2 ml of 50 nM FITC-MLL peptide alone in assay buffer was added. The assay performed with an average Z’ value of
0.5 and was tolerant up to 5% DMSO. For compounds with an IC50 < 2.0 mM and Ki < 1 mM, the 10-mer-Thr-FAM probe and FPA
protocol described below was used for enhanced sensitivity.
For the 10-mer-Thr-FAM peptide TR-FRET assay, LanthaScreen Elite Tb-anti His antibody (Tb-Ab) was purchased from Thermo-
Fisher and used at 1 nM. The 10-mer-Thr-FAM peptide was used at 150 nM, while WDR5-His-SUMO tag protein was used at 2 nM.
The working assay buffer composition was modified to pH 7.2 (1X Phosphate Buffered Saline, 300 mM NaCl, 0.5 mM TCEP, 0.1%
CHAPS). Stock compounds were dispensed to a white, flat-bottom OptiPlate plate (PerkinElmer) using an Echo Liquid Handler.
A 10-point, 5-fold dilution scheme with a top concentration of 5 mM (0.003 nM low concentration) was used with a final volume of
20 ml. Both the top concentration and the dilution scheme was adjusted to fit the anticipated potency of the compounds. Using
the above probe concentration and assay conditions, the calculated lower Ki limit was 0.060 ± 0.020 nM. Positive control wells
(0% displacement) consisted of 10-mer-Thr-FAM probe and WDR5/Tb antibody mix occupying columns 2 and 24, while negative
control wells (100% displacement) consisting of the protein/terbium antibody mix alone occupy columns 1 and 23. The assay
performed with an average Z’ value of 0.7 and was found to be tolerant to up to 5% DMSO.
For IC50 determinations, plates were covered, shielded from light, and incubated for 1h at room temperature with rocking. For the
FPA assay measurements, anisotropy was measured using an excitation wavelength of 480 nm and an emission wavelength of
535 nm. For the TR-FRET assay, measurement plates were excited at a wavelength of 340 nm, and emission wavelengths of 495
and 520 nmwere used. The ratio of the 520/495wavelengths were used to assess the degree of the FRET signal and resulting peptide
displacement. TR-FRET plate positive control wells include columns 2 and 24 containing 10-mer-Thr-FAM peptide, His-SUMO-
WDR5, and Tb-anti-His antibody to measure maximum signal from the FRET response. The change in anisotropy (FPA) or 520 /
495 emission ratio (TR-FRET) was used to calculate an IC50 (inhibitor concentration at which 50% of the bound peptide is displaced)
by fitting the inhibition data using XLFit software (Guilford, UK) to single-site binding model. This was converted into a binding
inhibition/displacement constant (Ki) using the formula (Nikolovska-Coleska et al., 2004):
Compound Ki = ½I50
½L50

Kpepd + ½P0

Kpepd + 1

where [I]50 is the concentration of the free inhibitor at 50% inhibition, [L]50 is the concentration of the free labeled ligand at 50%
inhibition, [P]0 is the concentration of the free protein at 0% inhibition, and Kd
pep represents the dissociation constant of the
FITC-MLL or 10-mer-Thr-FAM probe.
Surface Plasmon Resonance
SPR measurements were performed at XTAL Biosciences with compounds and purified WDR5 provided by us. SPR measurements
were performed using a BiOptix 404pi enhanced surface plasmon resonance (eSPR) instrument. Compounds C3 and C6 were pre-
pared as DMSO soluble stock solutions at 30 mM DMSO. His-SUMO-WDR5(22-334) protein was placed onto two channels (in
parallel). The conditioned biosensor NTA-biosensor chip was first charged with Ni2+ to allow for pre-concentration and then chem-
ically activated with EDC/NHS. His-tagged protein ligand at 100 nM in running buffer (PBS, 2 mM DTT, 50 mM EDTA, 0.05% Tween-
20, with no DMSO) was covalently attached to the dextran surface via amide coupling at 5 mL/min for 100 s. The His-SUMO-
WDR5(22-334) protein (PBS + 2mM DTT buffer) was then loaded onto channel 3 and channel 4 of the biosensor chip at 7,000
RU, leaving channels 1 and 2 unbound as reference. A solution of 1 M ethanolamine was injected for 1200 s at 20 mL/min to block
any free reactive carboxyls across all channels. For analyte binding, the BiOptix was run in 2x2mode. Analyte compounds C3 and C6
were first passed over one of these reference channels before coming into contact with the bound protein on channels 3 or 4. An
8-point, 3-fold serial dilution assay was performed in duplicate for compounds C3 and C6 starting at 100 nM and going down to
90 pM. DMSO stocks of compounds were diluted in running buffer with a final 1% DMSO. Association times were increased from
240 to 800 s by decreasing the flow rate to 30 mL/min. An 800 s dissociation phase followed. Saturation was achieved in order to
measure steady state binding as well as kinetics. Buffer blanks were inserted after every forth injection. A series of five DMSO stan-
dards between 0.5% and 1.5% were included with each run to correct for bulk refractive index. Sensorgrams were analyzed using
Scrubber 2 software with a double reference to determine the interaction parameters KD, kon, and koff. The reference channel was
first subtracted from the ligand channel. Next the bulk shift was corrected for using the DMSO standards included with each run.Cell Reports 26, 2916–2928.e1–e13, March 12, 2019 e5
The internal blank injections were then averaged and subtracted from compound injections. Binding data was fit to a 1:1 Langmuir
model. Each sensorgram is fit to a standard scale.
Histone Methyltransferase Assays
HMT inhibition activity assays were performed at Reaction Biology Corp. Details are under ‘‘Critical Commercial Assays’’ in the Key
Resources Table.
Compound Synthesis and Characterization
Compounds C1 andC4 are were purchased from commercial vendors andwere derived as hits from the Vanderbilt Fragment Library.
Compound 1 (CAS: 1334103-40-0), Compound 4 (CAS: 876709-30-7).
Compound C2 – N-(1-(3-Chlorophenyl)ethyl)-3-(((4,5-dihydro-1H-imidazol-2-yl)amino)methyl)benzamide
3-(N-Boc-aminomethyl)benzoic acid (251 mg, 1.0 mmol) and DIPEA (522 mL, 3.0 mmol) were taken in CH2Cl2 (5 mL) and cooled to
0C. HATU (570 mg, 1.5 mmol) was added and the mixture stirred for 30 mins before the addition of 1-(3-chlorophenyl)ethanamine
(156 mL, 1.1 mmol). The solution was allowed to warm to r.t. and stirred for 16 h. Upon completion, the mixture was diluted with
CH2Cl2 (5 mL) and washed with H2O (10 mL), concentrated, and purified by flash column chromatography (12 g, 0 – 40% EtOAc
in hexanes) to afford the intermediate tert-Butyl (3-((1-(3-chlorophenyl)ethyl)carbamoyl)benzyl)carbamate as a colorless solid
(228 mg, 0.59 mmol, 59%). This was dissolved in CH2Cl2 (3 mL), TFA (1.5 mL) was added and the mixture was stirred at r.t. for
2 h. The mixture was concentrated in vacuo to afford the crude amine intermediate as a TFA salt (assumed quantitative). The amine
was dissolved in anhydrous THF (2 mL) under an inert atmosphere and 2-methylthio-2-imiazoline hydroiodide (120 mg, 0.49 mmol)
and DIPEA (209 mL, 1.2 mmol) were added. The mixture was stirred at 40C for 16 h, venting through a scrubber of NaOH. Upon
completion, the solution was concentrated, taken in EtOAc and washed with NaOH (2 M), brine, and purified by preparative
HPLC. The combined fractions were re-dissolved in EtOAc and washed with sat. aq. K2CO3 and dried (MgSO4) to afford C2 as
the free base. 1H NMR (600 MHz, MeOH-d4) H 7.83 – 7.79 (m, 1H), 7.80 – 7.76 (m, 1H), 7.52 – 7.47 (m, 2H), 7.42 – 7.38 (m, 1H),
7.33 – 7.29 (m, 2H), 7.26 – 7.22 (m, 1H), 5.20 (q, J = 7.1 Hz, 1H), 4.45 (s, 2H), 3.71 (s, 4H), 1.56 (d, J = 7.1 Hz, 3H); LCMS (ESI)
tR = 0.85min, m/z = 357.3 [M+H]
+;R 95% (215, 254 nm); HMRS (ESI-TOF) calculated for C19H22ClN4O = 357.1477 [M+H]
+, observed
357.1477.
Compound C3 – 3-(((4,5-dihydro-1H-imidazol-2-yl)amino)methyl)-N-(3,5-dimethoxybenzyl)-4-fluorobenzamide
To a solution of methyl 4-fluoro-3-methylbenzoate (5.0 g, 29.7 mmol) in CCl4 (60 mL) was added NBS (5.5 g, 30.9 mmol) and AIBN
(0.20 g, 1.20 mmol). The mixture was heated to reflux for 18 h, then cooled, filtered and the filtrate was concentrated. The crude
material was purified by flash column chromatography to afford methyl 3-(bromomethyl)-4-fluorobenzoate (3.6 g, 14.6 mmol,
49%). A portion of the brominated intermediate (2.0 g, 8.10mmol) was dissolved in a 90%MeOH/water solution (40mL) and to which
sodium azide (0.78 g, 12.1 mmol) was added. The mixture was then heated to reflux for 2 h. The solution was cooled, concentrated,
re-dissolved in CH2Cl2, and extracted with H2O. The organic phase was dried (MgSO4) and concentrated to afford the crude azide
intermediate. The intermediate was dissolved in a solution of THF (20 mL), MeOH (5 mL) and water (3 mL) and then treated with LiOH
(2.0 M, 2.2 mL, 4.4 mmol) for 2 h at r.t.. The solvent was removed under reduced pressure, diluted with water, and acidified with HCl
(1 N) to a pH = 1. The resulting solid was collected by filtration, washed with water, and dried under high vacuum to afford 3-(azido-
methyl)-4-fluorobenzoic acid (1.58 g, quant.), which was used without further purification. A portion of the benzoic acid intermediate
(195mg, 1.0 mmol) in DMF (4mL) was cooled to 0C before the addition of DIPEA (435 mL, 2.5 mmol) and HATU (399mg, 1.05 mmol).
After 5mins, (3,5-dimethoxyphenyl)methanamine (166 mL, 1.1mmol) was added. Themixture was stirred for 18 h, then concentrated.
The crude mixture was dissolved in ethyl acetate, extracted with water and dried over MgSO4, filtered, and concentrated. The crude
amide intermediate was used without further purification. A solution of crude 3-(azidomethyl)-N-(3,5-dimethoxyphenyl)-2-fluoroben-
zamide (370 mg, 1.1 mmol) in EtOH (20 mL) was treated with Raney-Ni (0.1 g) and then stirred under an atmosphere of H2 for 2 h. The
catalyst was removed by filtration, and the solvent was removed under reduced pressure. The crude mixture was then dissolved
in pyridine (5 mL), and 2-methylthio-2-imidazoline hydroiodide (0.31 g, 1.28 mmol) was added. This mixture was heated under mW
irradiation at 125C for 1 h. The solvent was removed under reduced pressure, and the material was purified by preparative
HPLC. The combined fractions of product were dissolved in EtOAc and washed with sat. aq. K2CO3. The organic layer was dried
(MgSO4), and the solvent was removed under reduced pressure to afford C3 as the free base (220 mg, 0.57 mmol, 57%).
1H NMR (600 MHz, MeOH-d4) dH 7.92 – 7.85 (m, 2H), 7.26 (dd, J = 9.9, 8.4 Hz, 1H), 6.50 (d, J = 2.2 Hz, 2H), 6.37 (t, J = 2.2 Hz,
1H), 4.51 (s, 2H), 4.49 (s, 2H), 3.75 (s, 6H), 3.73 (s, 4H); 19F NMR (376 MHz, MeOH-d4) dF 115.5; 13C NMR (151 MHz, MeOH-d4)
dC 167.2, 163.4, 161.8, 161.1, 160.0, 140.9, 130.9, 130.9, 128.9 (d, J = 9.2 Hz), 128.7 (d, J = 4.9 Hz), 124.0, 123.9, 115.4
(d, J = 22.1 Hz), 105.1, 98.4, 54.3, 43.3, 42.8, 40.1, 40.0; LCMS (ESI) tR = 0.90 min, m/z = 387.1 [M+H]
+; R 95% (215, 254 nm);
HMRS (ESI-TOF) calculated for C20H24FN4O3 = 387.1827 [M+H]
+, observed 387.1828.
Compound C3nc – 3-(((4,5-dihydro-1H-imidazol-2-yl)amino)methyl)-N-(3,5-dimethoxybenzyl)-2-fluorobenzamide
C3nc was synthesized following the same synthetic route as used for Compound 3, starting from methyl 3-(bromomethyl)-2-fluoro-
benzoate. 1H NMR (600 MHz, MeOH-d4) dH 7.66 (td, J = 7.5, 1.8 Hz, 1H), 7.51 (td, J = 7.5, 1.8 Hz, 1H), 7.30 (t, J = 7.5 Hz, 1H), 6.53
(d, J = 2.3 Hz, 2H), 6.38 (t, J = 2.3 Hz, 1H), 4.51 (br s, 4H), 3.76 (s, 6H), 3.73 (s, 4H); 19F NMR (376MHz, MeOH-d4) dF121.6; 13C NMR
(151 MHz, MeOH-d4) dC 165.3, 161.2, 159.9, 158.6, 157.0, 140.6, 131.5 (d, J = 4.3 Hz), 129.8 (d, J = 2.9 Hz), 124.5 (d. J = 4.3 Hz),e6 Cell Reports 26, 2916–2928.e1–e13, March 12, 2019
124.4, 124.3, 123.9, 123.8, 105.0, 98.6, 54.3, 43.2, 42.8, 40.1 (d, J = 5.3 Hz); LCMS (ESI) tR = 0.70 min, m/z = 387.3 [M+H]
+;R 95%
(215, 254 nm); HMRS (ESI-TOF) calculated for C20H24FN4O3 = 387.1827 [M+H]
+, observed 387.1831.
Compound C5 – 3-((1H-Imidazol-1-yl)methyl)-N-(3,5-dichlorobenzyl)benzamide
3-(Chloromethyl)benzoyl chloride (142 mL, 1.0 mmol) was dissolved in CH2Cl2 (5 mL) and cooled to 40C in an acetonitrile/dry-ice
bath before the addition of DIPEA (348 mL, 2.0mmol) and 3,5-dichlorobenzylamine (133 mL, 1.0mmol). Themixture was stirred for 1 h,
allowing to warm to 0C, then concentrated in vacuo, and re-dissolved in THF (5 mL). In a separate vial imidazole (82 mg, 1.2 mmol)
and NaH (60% dispersion in mineral oil, 100mg, 2.5 mmol) were taken in THF (2.5 mL) and stirred for 30 mins. The crude aryl chloride
was added into the flask and heated to reflux for 18 h. The cooled mixture was diluted with EtOAc and washed with sat. aq. NH4Cl,
brine and purified by flash column chromatography (12 g, 0%–10% MeOH in CH2Cl2) to afford the title compound as a pale-yellow
solid (188 mg, 0.52 mmol, 52%). 1H NMR (600 MHz, MeOH-d4)H 7.80 (dt, J = 7.7, 1.5 Hz, 1H), 7.79 – 7.75 (m, 2H), 7.48 (t, J = 7.7 Hz,
1H), 7.42 (dt, J = 7.9, 1.4 Hz, 1H), 7.32 (t, J = 1.9 Hz, 1H), 7.30 (d, J = 1.9 Hz, 2H), 7.13 (q, J = 1.4 Hz, 1H), 6.99 (t, J = 1.4 Hz, 1H), 5.29
(s, 2H), 4.52 (s, 2H); 13C NMR (151 MHz, MeOH-d4) dC 168.3, 143.0, 137.7, 137.3, 134.8, 134.6, 130.6, 128.9, 128.1, 128.1, 126.7,
126.6, 126.4, 125.8, 119.5, 119.5, 49.8, 42.2; LCMS (ESI) tR = 0.86 min, m/z = 360.3 [M+H]
+ (dichloro splitting visible); R 95%
(215, 254 nm); HMRS (ESI-TOF) calculated for C18H16Cl2N3O = 360.0665 [M+H]
+, observed 360.0645.
Compound C6 – N-(3,4-Dichlorobenzyl)-3-(6-fluoro-2-methylpyridin-3-yl)-5-((2-imino-3-methyl-2,3-dihydro-1H-
imidazol-1-yl)methyl)benzamide
Argon gas was bubbled into a mixture of methyl 3-bromo-5-(hydroxymethyl)benzoate (7.50 g, 30.6 mmol), K2CO3 (10.69 g,
72.5mmol) and 80%1,4 dioxane / water (665mL) for 5min before the addition of Pd(PPh3)4 (2.68 g, 2.32mmol) and (6-fluoro-2-meth-
ylpyridin-3-yl)boronic acid (6.4 g, 41.5 mmol). The reaction was heated to 80C for 6 h, then the solvent was removed under reduced
pressure. The crude mixture was dissolved in CH2Cl2, extracted with water, dried with MgSO4, filtered, concentrated and purified by
flash column chromatography to afford methyl 3-(6-fluoro-2-methylpyridin-3-yl)-5-(hydroxymethyl)benzoate (7.19 g, 26.1 mmol,
83%). This was dissolved in THF (200mL) / MeOH (50mL) / water (50ml) and stirred with LiOH (1.13 g, 54.0mmol) for 6 h. Themixture
was concentrated, diluted with water, and the pH was adjusted to 1 with HCl (1N). The resulting solid was collected by filtration,
washed with water, and dried under vacuum to afford 3-(6-fluoro-2-methylpyridin-3-yl)-5-(hydroxymethyl)benzoic acid (6.20 g,
23.7 mmol, 91%). A portion of the benzoic acid intermediate (4.0 g, 15.3 mmol) in DMF (70 mL) was treated with Et3N (6.30 mL,
45.9 mmol) and cooled to 0C in an ice/water bath. The mixture was treated with EDC (3.0 g, 16.1 mmol), HOBT (2.46 g,
16.1 mmol), stirred for 5 mins, and then treated with (3,4-dichlorophenyl)methanamine (2.96 g, 16.8 mmol) for 18 h. The DMF was
removed under reduced pressure, and the crude mixture was dissolved in EtOAc, extracted with water, dried over MgSO4, filtered,
concentrated and purified by flash column chromatography to afford N-(3,4-Dichlorobenzyl)-3-(6-fluoro-2-methylpyridin-3-yl)-5-
(hydroxymethyl)benzamide (3.87 g, 9.23 mmol, 60%). This intermediate was dissolved in CH2Cl2 (100 mL) / toluene (200 mL) cooled
to 0C in an ice/water bath and treated drop-wise with PBr3 (1N, 9.7 mL, 9.7 mmol), upon complete addition the mixture was stirred
for 18 h. The reactionmixture was treated with water and NaHCO3 (s) until a basic pHwas obtained. The organic layer was separated,
washed with water, dried over MgSO4, filtered, concentrated and purified by flash column chromatography to afford 3-(bromo-
methyl)-N-(3,4-dichlorobenzyl)-5-(6-fluoro-2-methylpyridin-3-yl)benzamide (2.81 g, 5.83 mmol, 63%). The bromo intermediate,
DIPEA (2.55 mL, 14.5 mmol), and 1-methyl-1H-imidazol-2-amine (1.13 g, 11.60 mmol) were taken in MeCN (150 mL) and heated
to 80C for 18 h. The reaction was cooled, concentrated, and purified by reverse-phase HPLC. The combined fractions of product
were dissolved in EtOAc and washed with sat. aq. K2CO3. The organic layer was dried (MgSO4), and the solvent removed under
reduced pressure to afford C6 (1.79 g, 3.70 mmol, 63%). 1H NMR (600 MHz, MeOH-d4) dH 7.83 – 7.77 (m, 3H), 7.50
(d, J = 2.1 Hz, 1H), 7.47 (d, J = 8.3 Hz, 1H), 7.44 (t, J = 1.7 Hz, 1H), 7.28 (dd, J = 8.3, 2.1 Hz, 1H), 6.98 (dd, J = 8.4, 2.8 Hz, 1H),
6.89 (d, J = 2.6 Hz, 1H), 6.86 (d, J = 2.5 Hz, 1H), 5.19 (s, 2H), 4.54 (s, 2H), 3.49 (s, 3H), 2.38 (s, 3H); 19F NMR (376 MHz, MeOH-d4)
dF 72.2; 13C NMR (151 MHz, MeOH-d4) dC 167.5, 163.1, 161.5, 154.5, 147.2, 143.1 (d, J = 8.2 Hz), 139.7 (d, J = 26.2 Hz), 135.9,
135.2, 131.9, 131.0, 130.6, 130.3, 129.3, 127.5, 127.2, 125.7, 117.0, 115.0, 106.5 (d, J = 37.1 Hz), 42.2, 31.7, 21.3; LCMS (ESI)
tR = 0.91 min, m/z = 498.3 [M+H]
+ (dichloro splitting visible);R 95% (215, 254 nm); HMRS (ESI-TOF) calculated for C25H23Cl2FN5O =
498.1258 [M+H]+, observed 498.1266.
Compound C6nc – N-(3,4-dichlorobenzyl)-3-(6-fluoro-2-methylpyridin-3-yl)-4-((2-imino-3-methyl-2,3-dihydro-1H-
imidazol-1-yl)methyl)benzamide
Compound C6nc was synthesized following the same synthetic route as for Compound 6, starting from methyl 3-bromo-4-(hydrox-
ymethyl)benzoate. 1H NMR (600 MHz, MeOH-d4) dH 8.00 (dd, J = 8.1, 2.0 Hz, 1H), 7.74 (d, J = 1.9 Hz, 1H), 7.59 (t, J = 8.2 Hz, 1H),
7.52 – 7.49 (m, 2H), 7.47 (d, J = 8.3 Hz, 1H), 7.28 (dd, J = 8.3, 2.1 Hz, 1H), 6.97 (dd, J = 8.2, 2.6 Hz, 1H), 6.86 (d, J = 2.6 Hz, 1H), 6.56
(d, J = 2.6 Hz, 1H), 4.88 (s, 2H), 4.54 (s, 2H), 3.44 (s, 3H), 2.19 (s, 3H); 19F NMR (357 MHz, MeOH-d4) dF 71.0; 13C NMR (151 MHz,
MeOH-d4) dC 167.3, 163.5, 161.9, 155.2 (d, J = 13.7 Hz), 146.1, 142.6 (d, J = 8.0 Hz), 139.6, 138.4, 135.7, 134.8, 131.9, 131.2
(d, J = 4.6 Hz), 130.6, 130.2, 130.2, 129.5, 129.4, 129.3, 127.7, 127.1, 117.3, 114.6, 106.4 (d, J = 37.1 Hz), 42.2, 31.7, 21.0;
LCMS (ESI) tR = 0.93 min, m/z = 498.3 [M+H]
+ (dichloro splitting visible); R 95% (215, 254 nm); HMRS (ESI-TOF) calculated for
C25H23Cl2FN5O = 498.1258 [M+H]
+, observed 498.1275.
Proliferation Assays
Cell proliferation was assayed using the Promega CellTiter-Glo Luminescent Kit. White, opaque, flat-bottomed 96-well plates were
used. 5,000 cells were seeded per well for all cell lines, except 2,000 cells were seeded for MA93, MA93Ras, and MA93 FLT3/ITD toCell Reports 26, 2916–2928.e1–e13, March 12, 2019 e7
prevent overgrowth. Cells were treated with 0.1%DMSO vehicle only and at least five two-fold dilutions of WDR5 inhibitors with a top
concentration of 50 mM. Final DMSOconcentrationwas 0.1% in all compound treatment experiments. Each concentration of inhibitor
was tested in triplicate wells and at least two biological replicates were performed. The total volume of cells with inhibitor was 100 ml
per well. 200 ml of sterile PBS was added to all of the empty wells around the edge of the plate to prevent evaporation. Plates were
incubated at 37C for 72 hours. After 72 hours, the plates were allowed to reach room temperature before adding 50 ml of CellTiter-Glo
reagent per well. Plates were incubated at room temperature, covered from light, for 30 minutes before the luminescence was
measured using the CellTiter-Glo protocol on a GloMax plate reader. MTS assay (Promega CellTiter 96 AQueous Non-Radioactive
Cell Proliferation Assay kit) was used to measure proliferation of RN2 cells. 2,500 cells were seeded into clear, flat-bottomed
96-well plates and treated with inhibitors as stated above. After a 72-hour incubation, 20 ml of MTS solution was added per well
and plates were incubated at 37C for 1.25 hours, then absorbance at 490 nm measured using a Bio-Rad iMark Microplate reader.
For both CellTiter-Glo and MTS assays, the raw luminescence values were normalized to the DMSO vehicle only wells and PRISM
software was used to generate GI50 values. Error bars on proliferation curves represent standard errors of the mean.
Growth and Viability Time Course
MV4:11 cells were plated at a density of 13 105 cells/ml and treated with 0.1% DMSO only, 2 mMC6 or 2 mMC6nc. After 1, 2, 3, and
6 days, cells were stained with trypan blue and counted using an automated cell counter. Viability and cell density was measured
three times for each sample at each time point, then averaged. On day 3, cells were spun down and resuspended in fresh media
with fresh compound added. DMSO and C6nc-treated cells were replated to 13 105 cells/ml to prevent overgrowth. The time course
was repeated with three biological replicates and error bars represent the standard error of the mean.
Cellular Thermal Shift Assay (CETSA)
CETSA was performed as described (Jafari et al., 2014). To determine the melting temperature of WDR5, K562 or MV4:11 cells were
dispensed into PCR tubes at a density of 1,000,000 cells/tube in 99 ml of DMEM. One microliter of DMSO was added to each tube
and the cell suspensionmixed by vortexing. Cells were then subjected to 3minutes of heat in a 96-well thermal cycler at temperatures
of 46, 50, 54, 58, 62, 66, 70, 74, 78, 82, 86, and 90C. Immediately after heating, cells were snap frozen in a CoolSafe Chamber (USA
Scientific) surrounded by dry ice. To perform the isothermal dose-response of compounds againstWDR5, K562 orMV4:11 cells were
dispensed into PCR tubes at a density of1,000,000 cells/tube in 99 ml of DMEM. Onemicroliter of compound, or DMSO, was added
to each tube, mixed by vortexing, and incubated at 37C for one hour. Cells were then heated at 79C for 3 minutes in a 96-well ther-
mal cycler. Immediately after heating, cells were snap frozen prior to lysate preparation. To prepare cell lysates, frozen cells were
subjected to six rapid freeze-and-thaw cycles. After the first thaw, 1 ml of protease inhibitor cocktail (Sigma) was added to the cell
lysates. Cell lysates were centrifuged at 4C and 20,000 3 g for 20 minutes. Samples were prepared by transferring 60 ml of super-
natant into 20 ml of NuPAGE 4X LDS sample buffer (ThermoFisher) with 5 ml NuPAGE Sample Reducing Agent (10X) (ThermoFisher)
and then heated for 15 minutes at 95C. Note that in this experiment, cells without the 3-minute heating served as 100% stabilization
and used for normalization purpose. Protein lysates were separated on a NuPAGE Novex 4%–12% Bis-Tris gel (ThermoFisher) and
transferred onto PVDFmembrane using an iBlot 2 Dry Blotting System (ThermoFisher). Membranes were blocked overnight with 5%
nonfat dry milk (BIO-RAD) in PBST–Phosphate Buffered Saline (ThermoFisher) with 0.5% Tween-20 (Sigma). Membranes were then
incubated for 1 hour with 1:1,000 of rabbit monoclonal anti-WDR5 (D9E1I) antibody, washed three times for 15 minutes in PBST,
incubated with 1: 1,000 anti-rabbit HRP linked IgG. After washing three times for 15 minutes in PBST, blots were incubated with
SuperSignal West Dura Extended Duration Substrate (ThermoFisher). The chemiluminescence signals were captured by BIO-RAD
CHEMDOC Imaging System, quantified by ImageQuant TL (GE Healthcare) and analyzed using Prism (GraphPad). Error bars on
proliferation curves represent standard errors of the mean. Two independent biological replicates were performed.
Quantifying Relative Protein Synthesis Rates
Protein synthesis rates were measured by pulsing cells with O-propargyl-puromycin (OPP) (Signer et al., 2014). Briefly, MV4:11 cells
were treated for 1, 2, 3 or 6 days with 2 mM of C6nc, 2 mM C6 or 0.1% DMSO vehicle control. At each time point, 2 million cells were
collected per sample and pulsedwith 50 mMOPP for 1 hour at 37C. For a positive control for inhibition of protein synthesis, 100 mg/ml
of cycloheximide was added to DMSO treated cells and incubated at 37C for 30 minutes prior to addition of OPP. Cells were then
washedwith ice-cold phosphate-buffered saline (PBS) and fixed in 500 mL of PBSwith 1%paraformaldehyde (PFA) for 15minutes on
ice, then washed again in PBS. Cells were permeabilized with 500 mL of PBS + 3% FBS + 0.1% saponin for 5 minutes then washed in
PBS + 3% FBS. The Click-it Cell Reaction Buffer Kit (Thermo C10269) was used to conjugate 500 nM Alexa Flour647-Azide (Thermo
A10277) to OPP following the manufacturer’s instructions. Samples were washed in PBS + 3% FBS, then resuspended in 1 mL PBS.
To control for background staining, a sample of DMSO treated cells was subjected to the same staining procedure, but no OPP was
added. Relative Alexa647 fluorescence was quantified using a Becton Dickinson (BD) LSR II flow cytometer and analyzed using
FlowJo software. At least 10,000 events were recorded per sample. Doublets were excluded prior to analysis. The time course
was repeated in biological triplicate with error representing standard error of themean. Flow Cytometry experiments were performed
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Cell Cycle Analysis
Cell cycle analyses were performed as described (Kim and Sederstrom, 2015), with slight modification. MV4:11 cells were treated for
0, 1, 2, 3 or 6 days with 2 mMC6, 2 mMC6nc, or 0.1%DMSO vehicle control. Fresh media and compound was added on day three. At
each time point, one million cells were collected per sample and washed once with PBS then resuspended in 500 ml of PBS. Cells
were fixed by adding cells drop-wise to 4.5 mL ice cold 70% ethanol while vortexing, then incubated for at least two hours at
20C. Cells were washed in FACS buffer (PBS with 2% FBS, 1 mM EDTA) then stained with 500 ml PI Staining Solution (PBS
with 10 mg/mL propidium iodide, 100 mg/mL RNase, 2 mM MgCl2) for 20 minutes at room temperature, protected from light.
Propidium iodide fluorescence was measured using a BD LSR II Flow Cytometer and cell cycle distribution was analyzed using
BD FACSDIVA software. At least 10,000 events were recorded per sample. Doublets were excluded prior to analysis of cell cycle
distribution. The time course was repeated with three biological replicates and error bars represent the standard error of the
mean. Flow Cytometry experiments were performed in the Vanderbilt University Flow Cytometry Shared Resource.
Induction of Apoptosis
MV4:11 cells were treated for 0, 1, 2, 3 or 6 days with 2 mM C6, 2 mM C6nc, or 0.1% DMSO only. Fresh media and compound was
added on day 3. As a positive control for apoptosis induction, cells were treated with 2 mMCamptothecin for 4 hours. 5x105 cells were
collected per sample and resuspended in 100 ml of 1x Annexin V Binding Buffer (Invitrogen V13246). 0.5 ml of Alexa Flour488-
conjugated Annexin V (Thermo A13201) was added per sample, then incubated for 15 minutes. Cells were resuspended in 400 ml
fresh 1x Annexin V Binding Buffer + 10 ng of propidium iodide and incubated for 10 minutes. Samples were then kept on ice and
Alexa Flour488 and propidium iodide fluorescence wasmeasured using a BD LSR II FlowCytometer and the percentage of apoptotic
cells was analyzed using FlowJo software. At least 10,000 events were recorded per sample. After doublet exclusion, an unstained
control sample was used to set the quadrant gating. The time course was repeated with three biological replicates and error bars
represent the standard error of the mean. Flow Cytometry experiments were performed in the Vanderbilt University Flow Cytometry
Shared Resource.
Immunofluorescence and Confocal Microscopy
General procedures for immunofluorescence were taken from (Nicolae et al., 2014). For nucleophosmin (NPM) staining, cells were
treated for 72 hours with 4 mM C6, 4 mM C6nc or 0.1% DMSO only. For ɣ-H2AX staining, cells were treated for 24 hours with
4 mMC6, 4 mMC6nc or 0.1%DMSOonly. As a positive control for DNA damage, cells were treated for 1 hour with 2 mMcamptothecin.
As a positive control for nucleolar stress, cells were treated with 5 nM actinomycin D for 6 hours (Burger et al., 2010). Cells were
washed once in PBS, then 100,000 cells/sample were attached to slides via a Cytospin for 3 minutes at 800 rpm. Cells were fixed
with 4% paraformaldehyde for 10 minutes at room temperature, followed by extraction with 0.3% Triton X-100 for 10 minutes on
ice. Slides were blocked with 5%BSA + 0.1% Triton X-100 in PBS for 30 minutes at room temperature. Primary antibody was added
(1:5,000 Abcam ab11174 for ɣ-H2AX, and 1:2,000 Sigma B0556 for NPM) in PBS with 3%BSA and incubated overnight at 4C. After
washing in PBS, secondary antibody [1 drop Alexa Fluor488 goat anti-Rabbit ReadyProbes Reagent (Thermo R37116) in 3 mL PBS
for ɣ-H2AX or 1:2,000 Alexa Fluor488 goat anti-mouse IgG (Thermo A11001) in 3% BSA in PBS for NPM] was added and incubated
for 1 hour at room temperature. Slides were washed in PBS, then nuclei were counterstainedwith 20 mMDRAQ5 in PBS for 10mins at
37C. Slides were mounted with ProLong Diamond Antifade mountant. Images were collected using a Leica TCS SP5 scanning
confocal microscope. Nuclear ɣ-H2AX staining intensity was quantified for all cells in 5 representative fields of view imaged with
the same laser power and gain settings with Fiji software (Schindelin et al., 2012) and plotted in Prism with error bars representing
the standard deviation. The ratio of nuclear to nucleoplasmic NPM staining in individual cells from two biological replicates was
quantified using Fiji and plotted in Prism with error bar representing the standard deviation. Prism was used to perform a one-
way ANOVA with a post hoc Dunnett’s test in order to compare the mean of each treatment to that of the DMSO-only treated control
sample for both themean nuclear gamma-H2AX signal and ratio of nucleolar to nucleoplasmic NPM staining quantifications. Level of
significance was determined using a 95% confidence interval.
Generation of Cell Lines Expressing Exogenous WDR5
pFlag-C2, which is a derivative of pcDNA3.1-Puro (+) encoding a FLAG tag for N-terminal fusions (Thomas et al., 2015), was used as
the backbone to insert sequences encoding either (i) amino acids 1-94 ofSaccharomyces cerevisiaeGAL4 fused to theHA epitope, or
full-length human WDR5. Generation of the F133A mutant was accomplished using whole plasmid PCR with Q5 polymerase and
primers WDR5–11 and WDR5–12 (Table S4). For production of stable transfectants, 40 mg of each plasmid was linearized by
Pvu I digest and transfected into HEK293 cells using the calcium phosphate method. After two days Puromycin was added to the
media at 1 mg/ml. Selection was complete, compared to cells transfected with pBluescript II SK(+), after approximately three weeks.
Lentiviral Production and Transductions
pLKO-p53-shRNA-941 and pLKO-p53-shRNA-427 plasmidswere a gift from ToddWaldman [Addgene plasmid # 25637 and # 25636
respectively; (Kim et al., 2007). Scrambled shRNA pLKO.1 plasmid was a gift from David Sabatini [Addgene plasmid # 1864; (Sarbas-
sov et al., 2005). pLKO.3Gwas a gift fromChristophe Benoist & DianeMathis (Addgene plasmid # 14748). To allow for GFP+ cell sort-
ing instead of puromycin selection of transduced cells, shRNA sequences from pLKO-p53-shRNA-941, pLKO-p53-shRNA-427, andCell Reports 26, 2916–2928.e1–e13, March 12, 2019 e9
scrambled shRNA pLKO.1 were cloned into the pLKO.3G vector using SpeI and NdeI restriction enzymes (NEB). to create plasmids
pLKO.3G-p53-shRNA-941, pLKO.3G-p53-shRNA-427, and pLKO.3G-shRNA-scrambled plasmids, respectively. These plasmids
were transfected into HEK293T cells along with the pCMV-Pax2 and pMD2 packaging vectors using the calcium phosphate method.
pCMV-Pax2 was a gift from Jonathan Epstein (Addgene plasmid # 36052) and pMD2.G was a gift from Didier Trono (Addgene
plasmid # 12259). Virus-containing media was harvested 24 and 48 hours post-transfection and filtered through a 0.45 mm filter.
For viral transduction, one million MV4:11 cells were resuspended in 2 mL RMPI-1640 + 10% FBS + 1% penicillin/streptomycin.
8 mg/ml polybrene and 1 mL of filtered virus was added to the cells and incubated for 20 minutes. Cells were centrifuged at 800 x g
for 30 minutes then gently resuspended and plated in a 6-well plate. Cells were incubated overnight at 37C. The transduction
procedure was repeated two more times. GFP+ cells were sorted using a BD FACSAria III with a 100 mm nozzle. Cell sorting was
performed in the Vanderbilt University Flow Cytometry Shared Resource. shRNA mediated knock-down of p53 in sorted GFP+ cells
was validated via western blot.
Generation of p53 null MV4:11 and Molm13 cell lines
Lentiviral production and transduction was completed as stated for shRNA knock-down experiments, above. plentiCRISPRv2, a gift
from Feng Zhang (Addgene plasmid # 52961), was modified to express a gRNA against p53 (GAGCGCTGCTCAGATAGCGA;
pLentiCRISPRv2–TP53) or EGFP (GAGCTGGACGGCGACGTAAA; pLentiCRISPRv2–EGFP). Two days after transduction, cells
were selected with 2 mg/ml of puromycin for eight days. After selection with puromycin, the resistant cell populations were cloned
by single cell sorting into a 96-well plate using a BD FACSAria III. Clones were validated for p53 knockout by western blot and
Tracking of Indels by Decomposition (TIDE) sequencing analysis (Brinkman et al., 2014). Proliferation assays and p53 induction blots
were done as for the p53 shRNA knockdown.
Chromatin Immunoprecipitation
Chromatin immunoprecipitation (ChIP) assays were performed as described (Thomas et al., 2015). Cells were treated with inhibitors,
as indicated, then washed in PBS and cross-linked with 0.75%–1% formaldehyde at room temperature for 10 minutes. The reaction
was quenched with 125mM glycine for 10minutes at room temperature, after which cells were washed with ice cold PBS. Cells were
lysed in Formaldehyde Lysis Buffer (50 mM HEPES pH 7.5, 140 mMNaCl, 1 mM EDTA, 1% Triton, 1% SDS, and Complete Protease
Inhibitor cocktail) using 250 ml of buffer per 1x107 cells, on ice, for 10 minutes. Chromatin was sheared by 25-minute sonication
(BioRuptor) to yield a mean chromatin size of 250 bp, and debris cleared by centrifugation. Sheared chromatin was diluted
10-fold in Formaldehyde Lysis Buffer without SDS before immunoprecipitation overnight at 4C using the appropriate antibody
and Protein A agarose. Chromatin from 6 million cells was used per reaction. Immune complexes were washed sequentially with
Low Salt Wash buffer (20 mM Tris pH 8.0, 150 mM NaCl, 2 mM EDTA, 1% Triton), High Salt Wash Buffer (20 mM Tris pH 8.0,
500 mM NaCl, 2 mM EDTA, 1% Triton), LiCl Wash buffer (25 mM LiCl, 1 mM EDTA, 1% Triton) and twice with TE (pH 8.0).
Protein–DNA complexes were de-crosslinked overnight at 65C in Elution Buffer (TE, 0.1% SDS, 40 mg Proteinase K).
Proteinase K was heat inactivated for 20 minutes 95C then 150 ml of TE was added. 1 ml of DNA was used in a 15 ml PCR reaction
using KAPA SYBR FAST qPCR Master Mix 2X Universal and quantified on an Eppendorf Realplex2 Mastercycler in triplicate. ChIP
signals were calculated as percent input. ChIP experiments were completed in biological triplicate with error bars representing the
standard error of the mean.
Chromatin Immunoprecipitation–Sequencing
MV4:11 cells were grown to 106 cells/ml and treated for 4 hours with 0.1%DMSO, 2 mMC6, or 2 mMC6nc. Cells were concentrated to
4 3 106 cells/ml in PBS and cross-linked with 1% formaldehyde for 10 minutes at room temperature followed by quenching with
125 mM glycine for 10 minutes. Cells were washed with ice-cold PBS and lysed in 250 ml 1% SDS FA Buffer (50 mM HEPES,
pH 7.5; 140 mMNaCl; 1 mM EDTA; 1% Triton X-100; 1% SDS; 1x Roche Protease Inhibitor, EDTA-Free) per 107 cells and incubated
on ice for 10 minutes. Chromatin was sheared with a Bioruptor (Diagenode, UCD-200) on highest setting, alternating between 30 s
on/30 s off, to achieve an average fragment size of 250 nucleotides; cellular debris was then cleared through centrifugation for
10 minutes at 16k g at 4C. Sheared chromatin was diluted ten-fold with 0% SDS FA Buffer to achieve a final concentration of
0.1% SDS and IgG or appropriate anti-WDR5 antibody added. Samples were rotated overnight at 4C. Protein-A agarose beads
(Roche, 11 134 515 001) were washed three times with 1% FA Buffer and blocked for 20 minutes on rotator with 10 mg BSA and
100 ml 1% SDS FA Buffer per 15 ml bed volume of Protein-A agarose beads. 100 ml blocked bead slurry was added to each sample
and rotated for 4 hours at 4C. Beads were washed by rotating beads for 5 minutes at room temperature with 1 mL of the following
buffers: once with Low Salt Buffer, once with High Salt Buffer; once with LiCl Wash Buffer; and twice with TE. Washed chromatin-
bound beads were suspended in 50 ml TE, 5 ml 1% SDS, and 1 ml Proteinase K and incubated overnight at 65C. The following
day, 300 ml TE was added and protein removed by phenol chloroform extraction. DNA was precipitated by adding 36 ml 3 M NaOAc,
pH 5.2, 10 mg glycogen, and 1 mL 100% ethanol and centrifugation for 10 minutes at 16k g at 4C. DNA pellets were washed once
with 70% ethanol and air-dried. DNA pellets were suspended in 100 ml TE and used for next generation sequencing (NGS) library
preparation. Indexed libraries were made using the DNA Ultra II Library Prep Kit for Illumina (New England BioLabs, Inc., E7645).
Library quality was assessed using the 2100 Bioanalyzer (Agilent) and libraries were quantitated using KAPA Library Quantification
Kits (KAPA Biosystems). Pooled libraries were subject to 50 bp single-end sequencing according to the manufacturer’s protocole10 Cell Reports 26, 2916–2928.e1–e13, March 12, 2019
(Illumina HiSeq 3000). Sequencing was performed by the Vanderbilt Technologies for Advanced Genomics (VANTAGE) Shared
Resource. Bcl2fastq2 Conversion Software (Illumina) was used to generate de-multiplexed Fastq files.
Subcellular Fractionation
These assays were performed as described (Me´ndez and Stillman, 2000). MV4:11 cells were treated for 4 hours with 36 mM C3 or
0.1% DMSO only. 1 x107 cells were collected and washed twice in PBS. Cells were resuspended in 200 ml Buffer A [10 mM HEPES,
pH 7.9, 10 mM KCl, 1.5 mM MgCl2, 0.34 M sucrose, 10% glycerol, 1 mM DTT (added fresh), 1x protease inhibitor cocktail (added
fresh)] and incubated on ice for 8 minutes. Samples were centrifuged at 1,300 x g at 4C for 5 minutes. The supernatant (S1 fraction)
and pellet (P1 fraction) were separated and S1 was clarified by high-speed centrifugation at 4C for 10 minutes. The resulting super-
natant (S2 fraction) was collected and the pellet (P2 fraction) was discarded. The P1 fraction was washed once with 500 ml Buffer A
and centrifuged 1 minute at 1,300 x g. The P1 fraction was lysed by resuspending in 100 ml Buffer B [3 mM EDTA, 0.2 mM EGTA,
protease inhibitor cocktail (added just before use)] and incubating for 30 minutes on ice, followed by centrifugation at 1,700 x g at
4C for 5 minutes. The resulting supernatant (S3 fraction) was separated from the chromatin-enriched pellet (P3 fraction). P3 was
washed once with 500 ml Buffer B and resuspended in 100 ml SDS sample buffer and boiled for 10 minutes. 5% of each fraction
was run on an 8% SDS-PAGE gel and protein distribution probed by western blotting.
Polysome fractionation
Polysome enrichment experiments were performed as previously described (Yang et al., 2006). Briefly, 153 106 MV4:11 cells were
plated with either 5 mM C6 or DMSO control for 24 hours and then lysed in Polysomal Buffer (10 mM MOPS, pH 7.2, 250 mM NaCl
2.5 mM MgOAc, 0.5% NP-40, 200 ug/ml heparin; containing 50 mg/ml cyclohexamide, 1 mM PMSF, 20 units of Superase Inhibitor,
and protease inhibitor cocktail for 10 min on ice. Debris were cleared by centrifugation. A portion of the supernatant representing the
total RNAwas served as the total RNA for extraction. Polysomes in the supernatant were recovered by centrifugation (100,000 x g) for
1 hr in a TLA 120.1 rotor. Pelleted polysomes were resuspended in polysomal buffer and all supernatant remaining served as the
monsomal fraction. RNA from total, polysomal, andmonosomal fractions were extracted using Trizol-LS (Thermo Scientific) followed
by purification andDNase treatment using Direct-zol RNAminiPrep (Zymol). All extracted RNAwas subjected to reverse transcription
using MuLV reverse transcriptase as described below. Differences in mRNA levels between fractions were quantified using an
Eppendorf Realplex2 Mastercycler using the Ct method. For each fraction, mRNAs of interest were normalized to GAPDH and
then the percent of the total RNA for monosomal or polysomal fractions was calculated. These final values representing the percent
monosomal or polysomal mRNA were then made relative to DMSO treatment.
Cycloheximide (CHX) Chase
MV4:11 cells were treated for 24 hours with 2 mMC6, 2 mMNutlin-3 or DMSO only. After 24 hours, two million cells were collected for
each treatment as the ‘‘time 0’’ sample. To the remainder of the sample, CHX was added to a final concentration of 50 mg/ml. At time
points of 15, 30, 60, 120, and 180 minutes, two million cells for each treatment were collected, snap frozen in liquid nitrogen, and
stored at 80C until processing. Cell pellets were lysed in 200 ml of Kischkel buffer (50 mM Tris pH 8.0, 150 mM NaCl, 5 mM
EDTA, 1% Triton X-100, protease inhibitor cocktail, 1 mM PMSF), extracts sonicated and then cleared by centrifugation. Laemmli
Sample buffer was added and samples were boiled for 10 mins before running on a 4%–20% mini-PROTEAN TGX gel (BioRad)
and transferring to PVDF membrane. Membranes were blocked in 5% milk in TBST for 20 minutes then probed with appropriate
antibodies.
RT-qPCR Quantification of mRNA Expression
Cells were lysed in 500 ml Trizol, after which total RNA was extracted using the Zymo Research Direct-zol RNA MiniPrep kit with
on-column DNase digestion. After extraction, 1 mg of RNA was reverse transcribed using MuLV reverse transcriptase (Life Tech
N8080018) in 20 ml reaction, then diluted three-fold with nuclease-free water. 1 ml of cDNA was used in a 15 ml qPCR reaction using
KAPA SYBR FAST qPCR Master Mix 2X Universal and quantified on an Eppendorf Realplex2 Mastercycler in triplicate. Relative
mRNA expression of genes of interest was quantified using the CT method, normalized to signals from GAPDH. mRNA expression
studies were completed in triplicate with error bars representing the standard error of the mean.
PRO-Seq
30million MV4:11 cells were treated with compound C3 and harvested after either 15, 30, or 60 minutes. As a reference control, cells
were treated with 0.1% DMSO for 60 minutes. Cells were washed twice with cold PBS, resuspended in 10 mL of cold swelling buffer
(10 mM Tris-Cl pH 7.5, 2 mM MgCl2, 3 mM CaCl2, 300 mM Sucrose, protease inhibitors), and incubated on ice for 5 minutes. After
incubation, cells were pelleted by centrifugation, resuspended in 2 mL cell lysis buffer (swelling buffer + 10% glycerol + 0.1% Triton
X-100) and incubated on ice for 5minutes. Cells were thenDounce-homogenized 50 times, after which 5mL of lysis buffer was added
and nuclei collected by centrifugation. The nuclei were washed once with 5 mL lysis buffer, followed by one wash with 1 mL freezing
buffer (50 mM Tris-Cl pH 8.3, 40% glycerol, 5 mM MgCl2, 0.1 EDTA), resuspended in freezing buffer at density of 2 3 10
7 nuclei/
100 ml, and stored at 80C until nuclear run-on assays could be performed.Cell Reports 26, 2916–2928.e1–e13, March 12, 2019 e11
Nuclear run-on assays were performed as described (Kwak et al., 2013). Briefly, nuclei were thawed on ice and 2 3 107/100 mL
nuclei added to an equal volume of pre-warmed 2x nuclear run-on reaction mix (10 mM Tris-Cl pH 8.0, 300 mM KCl, 1% Sarkosyl,
5 mMMgCl2, 1 mMDTT, 375 mMATP, biotin-11-CTP, GTP and UTP, and 0.8 U/ml SuperaseIN). Run-on reactions were performed for
three minutes at 30C, and then terminated by addition of three volumes of TRIzol LS. RNA was extracted and precipitated in
isopropanol, followed by a 75% ethanol wash. Extracted RNA was fragmented by base hydrolysis using 0.2 M NaOH on ice for
10 minutes. After incubation, the reaction was neutralized by addition of one volume of 1 M Tris-Cl, pH 6.8. Thirty microliters of
DynabeadsMyOne Streptavidin T1 magnetic beads (Invitrogen) were then added to collect biotinylated RNA fragments, and incu-
bated on a nutator for 20 minutes at room temperature according to the manufacturer’s instructions. After incubation, beads were
sequentially washed with high salt (2M NaCl, 50 mM Tris-Cl pH 7.4, 0.5% Triton X-100), medium salt (300 mM NaCl, 10 mM Tris-Cl
pH 7.4, 0.1% Triton X-100), and low salt (5 mM Tris-Cl pH 7.4, 0.1% Triton X-100) wash buffers. RNA was eluted from the beads by
two TRIzol extractions followed by isopropanol precipitation and a 75% ethanol wash.
30 RNA adaptor ligation was carried out in a 10 mL reaction containing 10 pmol of 30 RNA adaptor, 10 U T4 RNA ligase I (NEB),
10 nmol of ATP, and SuperaseIN, at 20C for 6 hours. Adaptor-ligated biotinylated RNA was purified by Streptavidin bead binding
and RNA extraction as described above. The 50 ends of RNA fragments were repaired by incubation with Tobacco Acid Pyrophos-
phatase (TAP, Epicenter), followed by Polynucleotide Kinase (PNK, NEB) treatment according to manufacturer’s instructions. RNA
was extracted using TRIzol and precipitated with isopropanol followed by a 75% ethanol wash. 50 RNA adaptor ligation was carried
out in a 10 mL reaction containing 10 pmol of 50 RNA adaptor, 10 U T4 RNA ligase I, 10 nmol ATP, and SuperaseIN, at 20C for 6 hours.
Adaptor-ligated biotinylated RNA fragments were purified by Streptavidin bead binding and TRIzol extraction as described above,
and then reverse-transcribed using 25 pmol RP1 primer (for TRU-seq sequencing). An aliquot of cDNA was serially diluted and used
for standard PCR amplification to determine optimal PCR cycle number. The final library amplification was carried out by using
12.5 pmol RPI-index primers (for TRU-seq barcodes, Illumina) and Phusion polymerase (NEB). Libraries were run on PAGE gel
and and library fragments between 140 and 300 bp was excised. The libraries were purified and submitted to the Vanderbilt
Technologies for Advanced Genomics (VANTAGE) for sequencing on an Illumina HiSeq 2000.
RNA-Seq
Cells were treated for 72 hours with 2 mMC6, 2 mM C6nc or 0.1% DMSO only. Cells were washed in PBS then lysed in 500 ml Trizol.
RNA was isolated using the Zymo Research Direct-zol RNA MiniPrep kit with on-column DNase digestion following the manufac-
turer’s instructions. Library preparation with rRNA depletion and paired-end 150 base pair sequencing on an Illumina HiSeq was
performed by GENEWIZ. Prior to sequencing, RNA integrity was assessed by 2100 Bioanalyser (Agilent) and concentration was
assayed by Qubit. RNA-Seq for MV4:11 cells treated with C6nc, C6 and DMSO was completed with 5 biological replicates.
p53/p21 Induction Western Blots
Cells were treated for 24 hours with C6nc and C6 (2 mM for MV4:11 and 3 mM for Molm13), or 2 mM Nutlin-3, or a 0.1% DMSO only
vehicle control. Four million cells were washed in PBS then lysed for 10 minutes on ice in 200 ml Kischkel buffer (50 mM Tris pH 8.0,
150 mM NaCl, 5 mM EDTA, 1% Triton X-100, protease inhibitor cocktail, 1 mM PMSF). Whole cell extracts were sonicated for 15 s
then clarified by centrifugation. Laemmli Sample buffer was added and samples were boiled for 10 minutes before running on a
4%–20% mini-PROTEAN TGX gel (BioRad) and transferring to PVDF membrane. Membranes were blocked in 5% milk in TBST
for 20 minutes then probed with appropriate antibodies.
Induction of PARP1 cleavage
MV4:11 cells were treated for 1, 2, 3 or 6 days with 2 mM C6nc and C6, or 0.1% DMSO only. Four million cells were washed in PBS
then lysed for 10 minutes on ice in 200 ml Kischkel buffer (50 mM Tris pH 8.0, 150 mM NaCl, 5 mM EDTA, 1% Triton X-100, Protease
inhibitor cocktail, 1 mM PMSF). Whole cell extracts were sonicated for 15 s then clarified by centrifugation. Laemmli Sample buffer
was added and samples were boiled for 10 minutes before running on a 4%–20%mini-PROTEAN TGX gel (BioRad) and transferring
to PVDF membrane. Membranes were blocked in 5% milk in TBST for 20 minutes then probed with appropriate antibodies.
QUANTIFICATION AND STATISTICAL ANALYSIS
ChIP-Seq Data Analysis
ChIP-Seq reads were aligned to the human genome using Bowtie2 (Langmead et al., 2009). Peaks in each sample were called using
MACS2 with q-value of 0.01 (Feng et al., 2012). Peaks were annotated using the Homer command annotatePeaks (http://homer.
ucsd.edu/homer/). Consensus peaks in each condition were identified using DiffBind (Stark and Brown, 2011); peaks occurring at
least two replicates in each condition were included. Peaks identified in at least one condition were combined into a final peak
set to identify differential peaks across conditions. Read counts were normalized to the total mapped reads, and differential peaks
were determined by DESeq2 (Love et al., 2014), which calculated the log2 fold changes, Wald test p values, and adjusted p values
(False Discovery Rate, FDR) by the Benjamini-Hochberg procedure. Significantly changed peaks were assessed with FDR < 0.05.e12 Cell Reports 26, 2916–2928.e1–e13, March 12, 2019
RNA-Seq Data Analysis
RNA-Seq reads were aligned to the human reference genome hg19 using STAR (Dobin et al., 2013) and quantified by featureCounts
(Liao et al., 2014). Read counts were normalized by the Relative Log Expression (RLE) method. Differential analysis were performed
by DESeq2 (Love et al., 2014), which determined the log2 fold changes, Wald test p values, and adjusted p value (FDR) by the Ben-
jamini-Hochberg procedure. The significantly changed genes were assessed with a FDR < 0.05.
PRO-Seq Analyses
Low quality reads were trimmed from raw reads using Trimmomatic-0.32 (Bolger et al., 2014). Reverse complements were generated
using ‘‘fastx_reverse_complement’’ from FASTX-Toolkit. Reverse-complemented reads were aligned to the human genome hg19
using Bowtie2 [version 2.2.4; (Langmead and Salzberg, 2012). Reads mapped to rRNA loci and reads with mapping quality of
less than 10 were removed. The reads were normalized by the RLE implemented in the DESeq2 (Love et al., 2014). NRSA (http://
bioinfo.vanderbilt.edu/NRSA/), a tool to provide a comprehensive analysis on nascent transcriptional profiles for known genes
and novel enhancers, was used to estimate RNA polymerase abundance in proximal-promoter and gene body regions of genes,
to calculate pausing index and pausing index alterations, and to detect enhancers and quantify eRNA changes. Briefly, the pro-
moter-proximal region is defined by examining each 50 bp window with a 5 bp sliding step along the coding strand spanning ±
500 bp from known TSSs. The 50 bp region with the largest number of reads is considered as the promoter-proximal region and
its read density is calculated (Core et al., 2008). The gene body is defined as the region from +1 kb downstream of a TSS to its tran-
scription termination site (TTS). Pausing index for each gene is calculated as the ratio of promoter-proximal density over gene body
density. Significance of pausing is evaluated by Fisher’s exact test (Core et al., 2008). NRSA first calls novel transcripts using
HOMER, and then identifies intergenic, bidirectional transcripts as eRNA pairs (Hah et al., 2011, 2013). NRSA detects enhancers
by integrating those eRNA pairs. Enhancers are considered to be novel if their centers do not fall in any enhancer region based
on the FANTOM5 database (Lizio et al., 2015). DESeq2 (Love et al., 2014) was implemented to detect significant transcriptional
changes for promoter-proximal, gene body regions, and enhancers, accounting for the batch effect. Transcriptional changes
were assessed with a FDR < 0.05 and a fold changeR 1.5 were considered significant.
DATA AND SOFTWARE AVAILABILITY
All genomic datasets (for ChIP-Seq, RNA-Seq, and PRO-Seq) have been deposited at the Gene Expression Omnibus (GEO) with
accession number GEO: GSE115377. X-ray crystal structures have been deposited at the Protein Data Bank (PDB) with accession
codes PDB: 6DY7, 6EY1, 6E22, 6E1Z, 6DYA, and 6E23.Cell Reports 26, 2916–2928.e1–e13, March 12, 2019 e13
